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Dengue virus (DENV) infection is a major cause of morbidity and mortality 
in tropical and subtropical areas worldwide. Pathogenesis of dengue disease is 
not completely understood due to a lack of suitable experimental models for 
DENV infection, which hampers attempts to develop antiviral drugs and effective 
vaccines. It has been reported that the magnitude of immune responses correlate  
with severe dengue disease. We therefore wanted to characterize the DENV-
specific T cell, NK cell, and CD56+CD3+ T cell responses in patients with acute 
dengue infection to find potential targets for intervention and prognostic markers. 
 
As part of the on-going Early DENgue Infection and Outcomes (EDEN) 
Study in Singapore, fresh whole blood samples were analyzed from dengue 
patients longitudinally from fever onset to convalescence. We found that dengue 
patients exhibited significantly lower absolute counts of T cells, NK cells, and 
CD56+ T cells early after infection and significantly higher levels of T cell, NK cell, 
and CD56+ T cell activation compared to febrile non-dengue controls in the acute 
phase, which reflects an efficient activation of the immune response early after 
infection. The percentage of total activated cells did not significantly differ 
between dengue patients with primary and secondary infection, indicating that 
naïve T cells are as efficiently activated as memory T cells. We also show 
changes in the T cell compartments of dengue patients potentially leading to the 
10 | P a g e  
 
establishment of high numbers of memory cells. These changes did not 
significantly differ between primary and secondary dengue infection. Activation of 
naïve T cells and reactivation of memory T cells may be protective or disease-
enhancing. However, since all our cases were mild, we cannot address the 
question whether re-activation of T cell memory is potentially immunopathogenic, 
as suggested by others..  
 
Next, we established methods to detect dengue-specific T cells. Therefore, 
peripheral blood mononuclear cells from dengue patients and healthy dengue-
immune individuals were investigated by IFN-γ T cell ELISPOT and flow 
cytometry for their DENV-specific responses to peptides spanning conserved 
regions of the immunodominant NS3 epitope of DENV serotype 2 majority 
consensus sequence. The specificity of the T cell responses was donor-
dependent. IFN-γ responses of cultured PBMCs (in the absence of irradiated 
autologous PBMCs) from dengue-immune individuals after re-stimulation with 
peptide pools were analyzed by intracellular IFN-γ staining and flow cytometry. 
CD4+ and CD8+ T cell responses to peptide pools were observed at 7 and 23 
culture days for one out of the three dengue-seropositive donors. ELISPOT 
analysis of cells from the same donor at day 23 supported intracellular IFN-γ 
staining and flow cytometry data, where the NS3 peptide 
MCHATFTMRLLSPVR(261-275) was found to evoke the strongest response. The 
HLA restriction for this peptide in the Singaporean population could be further 
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characterized and responses to this epitope could be analyzed to determine the 
immunodominance of this epitope. As some HLA alleles have been linked to 
susceptibility to DHF and peptide epitopes have been associated with severe 
disease, further studies are warranted to increase our understanding of the 
pathology of severe dengue disease. 
 
Finally, we established T cell clones by antigen re-stimulation ex vivo to be 
able to characterize DENV-specific T cells. We succeeded in establishing T cell 
clones from a bulk culture of DENV-stimulated PBMCs from a healthy dengue-
immune individual. However, the predominantly CD4+ T cell clones had few IFN-
γ-producing cells and did not expand to numbers sufficient for T cell functional 
analyses. Our protocol could be further improved and refined to expand CD8+ T 
cell clones and to make clones expand to numbers sufficient for functional 
characterization of DENV-specific T cells in order to completely understand the 
protective or immunopathologic role of T cells and to identify reliable prognostic 
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Dengue infection is the most common mosquito-borne infectious disease 
in the world caused by a flavivirus called dengue virus (DENV). With an 
estimated 100 million people infected annually, and over 2 billion people at risk of 
infection in the tropics and subtropics globally (Halstead, 1988), dengue 
continues to pose a threat to public health. The disease is caused by the Aedes-
transmitted dengue viruses; a group of four antigenically related serotypes 
(designated DENV 1-4 in this thesis). DENV, a positive-sense single-stranded 
RNA virus belongs to the Flavivirus genus of the Flaviviridae family which include 
other viruses of public health importance like Japanese encephalitis virus (JEV), 
tick-borne encephalitis virus (TBEV), West Nile virus (WNV), and yellow fever 
virus (YFV) (Burke and Monath, 2001). Infection results in a range of clinical 
manifestations from asymptomatic to the severe, life-threatening dengue 
hemorrhagic fever (DHF) and dengue shock syndrome (DSS). The hallmark of 
DHF and DSS is plasma leakage that results from vascular permeability, 
resulting in significant fatality rate if not properly managed (Halstead, 1988). 
Currently, patient management remains mainly supportive because neither drug 
for antiviral therapy nor vaccine for disease prevention is available for dengue. 
 
Several years of basic and clinical research have yielded significant 
progress in understanding the pathogenesis of severe dengue diseases, yet 
many questions remain unanswered so far. Viral load by itself may not be solely 
responsible for the symptoms of severe dengue infections. While peak viral 
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replication correlates with disease, severe symptoms manifest themselves when 
viremia drops and not when the virus is actively replicating (WHO, 1997; Gubler, 
1998). 
 
It has been hypothesized that severe dengue may be caused by the 
patients‟ own immune response (Halstead, 1988) against the virus. Primary 
dengue infection-generated serotype cross-reactive antibodies or serotype cross-
reactive T-lymphocytes, or both, are activated and may contribute to 
immunopathology. Immunopathology could result from a shift of the fine balance 
from a normal host antiviral defense to the potentially damaging over-reacting 
immune responses. 
 
Antibody-dependent enhancement is widely believed to explain the link 
between immunological cross-reactivity and pathogenesis. During primary 
infection with one DENV serotype, antibodies generated against the infecting 
serotype do not give lasting protection against other serotypes. These cross-
reactive antibodies could enhance secondary infection with heterologous a virus 
by increasing virus-antibody immune complexes uptake into Fc-receptor bearing 
cells. This could result in more severe disease as virus titers are increased 
during secondary infection (Halstead, 1988).  
21 | P a g e  
 
Cross-reactive T-cell responses during secondary infection have also been 
implicated in pathogenesis and may synergize the effects of the enhancing 
antibody, resulting in overly activated immune responses. Cross-reactive 
cytotoxic memory T-cells produced against one DENV serotype during primary 
infection are activated during secondary infections with a different serotype, but 
are less efficient in eradicating the newly encountered serotype, leading to 
increased virus replication. Furthermore, activated memory T cells produce IFN-γ 
that upregulates Fc-receptor expression, potentially facilitating virus uptake via 
attachment to Fc-receptor by non-neutralizing antibodies, thus enhancing 
infection. In turn, T-cell activation is augmented, as well as secretion of pro-
inflammatory cytokines and other vasodilatory molecules (TNF-α, IFN-γ, IL-6, IL-
2) that may play a direct role in pathogenesis by promoting vascular leakage 
(Mongkolsapaya, 2003). 
 
The role of human natural killer (NK) cells and CD56-expressing T cells in 
dengue is not as well-studied. NK cells belong to a distinct subset of lymphoid 
cells and are constituents of innate immunity (Cerwenka and Lanier, 
2001).CD56-expressing human T lymphocytes are members of a heterogeneous 
group of T cells that includes CD4+, CD8+, and CD4-CD8- cells expressing 
MHC-or CD1d-restricted TCRs. They feature characteristics of both NK cells and 
T cells and have been shown to kill tumor cells via MHC-unrestricted 
perforin/granzyme-mediated cytolysis (Ortaldo et al., 1991; Pittet et al., 2000). 
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These cells also secrete IFN-γ, TNF-α, and IL-4 and display T cell-like cytotoxic 
activities restricted by MHC or CD1d and mediated by TCR (Ortaldo et al., 1991; 
Jin et al., 1998; Doherty et al., 1999; Metelitsa et al., 2001; Ohkawa et al., 2001). 
Both NK cells and CD56+ T cells serve as a first line of defense against a wide 
spectrum of pathogens, limiting their spread before the adaptive immune 
response is activated. T Lymphocytes displaying innate and adaptive functions 
could potentially regulate adaptive immunity against pathogens. NK cells and 
CD56+ T cells may therefore play a hitherto uncharacterized role during dengue 
infection and must therefore be investigated.  
 
In general, it is recognized that pathogenesis is multifactorial involving 
viral and host genetic, immunological, and other factors. The multiple 
mechanisms and complex interplay may be the reason for the unpredictable 
clinical outcomes, the occurrence of mild disease and the rare progression to 
DHF/DSS. The mechanisms leading to the development of DHF/DSS are not 
completely understood. This may be due in part, to the lack of both in vitro and in 
vivo animal disease models and the multiple factors that contribute to the 
development of disease. This, in turn, hampers the development of effective 
vaccines and therapeutic drugs. 
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The Early Dengue Infection and Outcomes (EDEN) Study, initiated during 
the 2005 dengue outbreak in Singapore, is a prospective longitudinal study  of 
patients with dengue and febrile non-dengue illness presenting early in the 
course of infection. This collaborative study involving several institutions in 
Singapore examines viral, clinical, host-specific, and epidemiological aspects of 
early dengue infection in adults (Low et al., 2006). The EDEN study has the 
advantage of examining patients in the early stages of infection, which may be 
difficult to achieve in many dengue endemic countries. The aims of the study are 
to improve clinical assessment and development of therapies for dengue.  
 
1.1 Objectives and Significance of the Study 
 
To increase our understanding of the complex clinical phenotype of 
dengue disease, we investigated the changes that occur in T cells, NK cells, and 
CD56+ T cells during infection in a cohort of Singaporean dengue patients. 
These immune responses may differ in dengue fever, DHF/DSS, and in other 
febrile illnesses, and hence can be used to distinguish among these illnesses 
and provide information that might be useful to predict the extent of disease 
severity at the early stage of infection. NK cell, T cell, and CD56+ T cell 
responses to dengue infection has not been explored in the Singaporean 
population. The Singapore dengue patient cohort is unique in terms of genetic 
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background and because of the fact that mostly adults are infected. Furthermore, 
dengue patients in Singapore were analyzed at the early stage of infection. 
Therefore, our results may provide unique insights on dengue immunopathology. 
 
 The specific objectives are as follows:  
 to phenotype T cells, NK cells, and CD56+CD3+ T cells from whole blood 
samples of dengue and febrile non-dengue patients during acute infection, 
defervescence, and convalescence by antibody labeling of cell surface 
markers and flow cytometry; 
 
 To examine subsets of T cell populations (memory, effector) present in the 
above-mentioned patient blood samples 
 
 To investigate DENV-specific responses to peptides based on 
immunodominant NS3 epitopes by IFN-γ T cell ELISPOT and intracellular 
cytokine staining for IFN-γ 
 
 To establish and characterize T cell clones that respond to DENV peptide 
stimulation by phenotypic analysis (CD3, CD4, CD8 markers) and IFN-γ 
production. 
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2.1 The Dengue Virus 
 
2.1.1 Virion Structure and Genome Organization 
 
The four antigenically-related but immunologically-distinct serotypes of 
dengue virus (DENV 1-4) belong to the genus Flavivirus of the Flaviviridae family, 
which comprise enveloped, positive-strand RNA viruses. The genus Flavivirus 
includess tick- and mosquito-borne viruses, and zoonotic viruses with unknown 
vector. Flaviviruses include Japanese encephalitis virus (JEV), tick-borne 
encephalitis virus (TBEV), West Nile virus (WNV), and yellow fever virus (YFV), 
which are important public health threats in endemic areas (Burke and Monath, 
2001) All four DENV serotypes are transmissible through bites of the mosquitoes 
Aedes aegypti and A. albopictus. 
 
The 50-nm spherical flavivirus virions contain an approximately 10.8 kb 
positive sense, single-stranded RNA (ssRNA) genome surrounded by an 
icosahedral capsid. The nucleocapsid consisting of the 12-14 kDa capsid protein 
is enclosed by a lipid bilayer derived from the host membrane, which contains the 
7-8 kDa membrane protein and the 55-60 kDa envelope protein (Lindenbach and 
Rice, 2003).  
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 The ssRNA genome possesses one open reading frame (ORF) that 
encodes a single polyprotein: 5‟-C-prM(M)-ENS1-NS2A-NS2B-NS3-NS4A-NS4B-
NS5-3‟. The amino terminus encodes 3 structural proteins: core (C) membrane 
(M), and envelope (E) proteins.  C protein plays a role in the packaging of the 
viral genome and in the formation of a nucleocapsid core. M protein is the 
proteolytic fragment resulting from prM cleavage and is crucial for virus 
maturation. The E protein is involved in receptor binding and fusion. 
 
The seven non-structural proteins are required in viral replication. The DENV 
RNA genome is modified at the 5‟ end by a type I cap structure, which is 
essential for mRNA stability and ribosome binding during mRNA translation, but 
lacks a polyadenylate tail. Flanking the genome are the 5‟ and 3‟ untranslated 
regions (UTRs), which are critical for efficient RNA replication and translation 
(Chiu et al., 2005). 
 
2.1.2 Replication Cycle 
 
DENV virions attach to host cells (mostly dendritic cells, 
monocytes/macrophages, hepatocytes, possibly also T and B lymphocytes, 
endothelial cells and neuronal cells) through interactions between the viral 
surface glycoprotein and cellular receptors (e.g. CD14-associated molecules, 
28 | P a g e  
 
DC-SIGN/CD209, GRP78/BiP, heparan sulfate) and are internalized into clathrin-
coated pits via receptor-mediated endocytosis (Clyde et al., 2006; Chen et al., 
1999; Jindadamrongwech et al., 2004; Navarro-Sanchez et al., 2003;  Stiasny 
and Heinz, 2006; Tassaneetrithep et al., 2003). DC-SIGN is probably the most 
significant cellular receptor for dengue infection. The carbohydrate recognition 
domain (CRD) of DC-SIGN was shown to interact with the N-glycosylated parts 
of the E protein (Pokidysheva et al., 2006).  
 
The virions are brought into a pre-lysosomal endocytic compartment 
where low pH induces conformational changes (trimerization of the dimeric E 
glycoprotein) in the viral envelope. The E protein comprises three ectodomains 
(domains I-III) with a fusion peptide at the tip of domain II, which becomes 
exposed due to the pH-induced conformational change, and inserts into the host 
membrane (Mukhopadhyay et al., 2005). This permits fusion with the endosomal 
membrane, which releases the nucleocapsid into the host cell cytosol.  
Upon release of the viral genome into the cytosol, the 5'UTR directs the 
RNA to the ribosomes to translate the single ORF into a precursor polyprotein at 
the surface of the endoplasmic reticulum (ER). Cellular proteases (signalases) 
and viral proteases co- and post- translationally process the polyprotein into 
individual and functional proteins. The structural proteins are translocated and 
attached into the ER by membrane anchor sequences. The prM protein, E 
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protein, and the NS proteins are found in the ER lumen while the capsid protein 
is attached to the ER outer membrane (Mukhopadhyay et al., 2005). 
 
  After viral RNA translation, the NS5 protein or the RNA-dependent RNA 
polymerase (RdRp) synthesizes the minus-strand ssRNA using the positive-
strand as template. The minus-strand then serves as template for the production 
of new positive-stranded ssRNA. The process occurs in complexes consisting of 
viral RNA and NS proteins. The replication complexes are associated with 
intracellular membranes.  
 
After genome replication, virus assembly ensues. This process proceeds 
with the formation of the nucleocapsid, consisting of one copy of the genomic 
RNA and multiple copies of the capsid protein. The assembled nucleocapsid then 
buds off as a complex into the ER lumen, resulting in the immature virion 
surrounded by a host-derived lipid envelope containing the prM and E  viral 
proteins. The process is highly coordinated by the membrane-associated capsid 
protein and the prM-E heterodimer in the ER.  
 
The envelope proteins are glycosylated as the immature virion is transported 
through the secretory pathway. At the trans-Golgi network, the prM protein is 
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cleaved by the protease furin to produce mature, infectious particles. Mature 
virions are finally released into the extracellular space by exocytosis.  
 
2.1.3 Transmission Cycle of DENV 
 
Figure 2.1 summarizes the DENV transmission cycle by its mosquito 
vector. 
Mosquito feeding on an infected human allows the virus to be taken up 
into the mosquito, where it begins to replicate in the mosquito gut cells. The 
incubation period in the insect vector lasts for 10 to 14 days and is called 
extrinsic phase of DENV life cycle. The intrinsic life cycle commences when the 
virus gets transmitted to humans from mosquito saliva during a subsequent blood 
meal and starts to infect DENV-permissive cells. DENV is detectable after an 
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Figure 2.1. The transmission cycle of DENV.  Virus circulates in the blood of an 
infected individual for about five days. An uninfected female Aedes aegypti 
bites the viremic person and ingests DENV-containing bloodmeal. DENV 
replicates within the vector for an 8-10-day extrinsic incubation period. The 
mosquito bites and transmits the virus to other individuals for the 
remainder of its lifetime. The virus then replicates in the subsequent 
individuals. After an average of 4-7 days (range 3-14 days) after the 
mosquito bite, symptoms begin to manifest (intrinsic incubation period). 





DENV are the only known arboviruses that have lost the need for an 
enzootic lifecycle for amplification and maintenance. They are fully adapted to 
humans and because of high level of viremia, they are transmitted efficiently by 
the domesticated A. aegypti mosquito. DENV may still be maintained through a 
rare sylvatic cycle in non-human primates involving other Aedes species as 
vectors. Human and sylvatic transmission cycles are independent of each other. 
(http://www.cdc.gov).  
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2.2 Dengue Epidemiology 
 
Dengue is an old disease and currently the most widespread mosquito-
borne human viral disease. The Chinese had described symptoms resembling 
those of dengue during the Chin dynasty (265 to 420 A.D.) (Gubler, 1998).  In 
1801, the acute febrile illness called “ka dinga pepo” (in Kiswahili/Swahili 
language) characterized by bone pains, hemorrhage, and jaundice had been 
described, from which the term “dengue” was derived (Rigau-Perez, 1998). It 
was shown by Ashburn and co-workers that this disease is caused by a virus. 
During WWII, DENV 1 and DENV 2 and the existence of homotypic immunity 
were described (Sabin, 1952). DENV 3 and DENV 4 were identified during an 
epidemic in Manila, Philippines in 1956 (Hammon et al., 1960).  
 
Dengue is a resurging global public health problem. Between the 17th and 
20th centuries, sporadic and widespread dengue outbreaks were a major public 
health problem (Gubler, 2004). At present, there are 100 million DF cases 
reported annualy (Halstead, 1988) and over 2 billion people are at risk worldwide 
(Gubler, 1998; Gubler, 2002a) (Figure 2.2). It is estimated that 500,000 dengue 
cases, mainly pediatric, need hospitalization each year and that 2.5-5% of these 
cases are fatal (WHO, 2002). Dengue epidemics have tremendous economic 
and social impact, particularly in developing countries in the tropics (Gubler, 
2002). 
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Figure 2.2. Countries are at risk of dengue transmission where DENV and A. 
aegypti occur. (www.cdc.gov/.../dengue/map-distribution-2005.htm) 
 
Dengue occurs in Africa, Central and South America, South and Southeast 
Asia, and in the Caribbean and Pacific regions, and is endemic in more than 90 
tropical countries. During and after WWII, Asia became hyperendemic with the 
co-circulation of multiple DENV serotypes, probably due to increased population 
density, the deployment of soldiers, movement of troops, and shipment of war 
material (Gubler, 2004). The increased transmission of multiple serotypes 
probably resulted in the emergence of DHF. The first DHF outbreak occurred in 
Manila, Philippines in the 1950s. In Singapore, the first DHF epidemic took place 
in the early 1960s. By the mid 1970s, DHF spread throughout Southeast Asia 
and had become a major pediatric burden (Gubler, 2004). In the Americas, the 
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first DHF cases were reported between 1981 and 1997. The dramatic 
epidemiological changes in the Americas may have been engendered by the 
suspension of the A. aegypti eradication programs in the early 1970s, with these 
mosquitoes reclaiming their geographic distribution, causing dengue outbreaks in 
countries known to be non-endemic or hypoendemic.  
 
Outbreaks are normally limited to the tropics due to DENV transmission by 
Aedes mosquitoes. However, contemporary demographic and lifestyle trends 
such as population explosion and uncontrolled urbanization resulted in the 
spread of dengue to non-endemic regions. The lack of mosquito control and the 
expansion of human mass transportation introduced novel DENV serotypes and 
strains into previously non-endemic geographic regions. Other factors that may 
have contributed to changes in dengue epidemiology are changes in public 
health policies and decay of public health infrastructures (Gubler, 2002a, Gubler, 








35 | P a g e  
 
2.3 Clinical Manifestations of Dengue Disease 
 
Dengue virus infection causes a broad spectrum of clinical symptoms, 
ranging from asymptomatic infection to severe and life-threatening DHF or DSS. 
After the bite of an infected mosquito, symptoms develop after an incubation 
period of an average of 4 days (Kautner et al., 1997). The various clinical 
manifestations of infection encountered are undifferentiated fever, classic dengue 
fever (DF), DHF, and DSS. 
 
2.3.1 Undifferentiated fever 
 
Dengue presents as a mild, atypical febrile illness that cannot be 
distinguished from other viral infections, and may be barely acknowledged as 
clinically significant.  Some patients are initially diagnosed with influenza, 
bronchitis, and or upper respiratory tract infection (Halstead, et al., 1969). A 
prospective study of dengue infections in Bangkok, Thailand reported that of the 
infected individuals, 87% were either asymptomatic or only mildly symptomatic 
(Burke et al., 1988). Dengue is a major cause of undifferentiated fever 
contributing one third of the fevers to the total burden of febrile illnesses 
presented to public primary health services in southern Vietnam (Phuong et al, 
2006). Subclinical undifferentiated fever is believed to be most common in 
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pediatric dengue cases (Halstead, et al., 1969), and may be the most common 
manifestation of dengue infections. 
 
2.3.2 Classic dengue fever 
 
Classic dengue fever is typically an acute influenza-like, self-limiting but 
nevertheless debilitating illness characterized by fever, frontal headache, retro-
orbital pain, myalgia (muscle pain), arthralgia (joint pain), nausea, vomiting, and 
rash (Clyde et al., 2006; Rigau-Perez et al., 1998; WHO, 1997). These symptoms 
are normally observed in older children and adults, while infants and young 
children may present minimal symptoms or are frequently asymptomatic (Burke 
et al., 1988). The illness lasts for 5 to 7 days then the fever abates. 
Convalescence ensues and full recovery may take weeks (Brooks, et al., 2007)  
 
2.3.3 Dengue hemorrhagic fever and dengue shock syndrome 
 
In general, replication of the virus is successfully controlled after the 
viremia phase. Individuals who recovered from illness would be immune for a 
lifetime against the primary infection dengue virus serotype. In a small number 
(3-5% of DENV-infected individuals) of cases, infection may progress to a more 
severe illness, DHF or DSS. Infection with any of the four DENV serotypes can 
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lead to DHF. DHF begins with an abrupt onset of fever, showing the symptoms of 
classical DF (Gubler, 1998) and typically develops around day 3–7 of illness at 
the time of defervescence and continues for 2–7 days. The cardinal features of 
DHF are increased vascular permeability ("plasma leakage"), thrombocytopenia 
(low platelet count; ≤105/μL), and hemorrhagic manifestations. Plasma leakage 
manifests as fluid accumulation in the pleural and/or abdominal cavity at the time 
of defervescence (WHO, 1986) and is documented by haemoconcentration, 
pleural effusions, hypoalbuminaemia or hypoproteinaemia. Plasma leakage 
usually does not last for more than 48 h and is generally followed by rapid and 
complete recovery. Plasma leakage in DHF occurs through endothelial gaps with 
a relative lack of tissue (capillary endothelium) inflammation and without necrosis. 
 
DSS is defined as DHF with signs of circulatory failure that includes 
narrow pulse pressure (≤20 mm Hg), hypotension, or shock. Increased 
probability of imminent shock is signified by progressively declining platelet count 
and rising haematocrit (Nimmannitya, 1987). Signals for impending shock are 
intense, sustained abdominal pain, persistent vomiting, restlessness or lethargy, 
and an abrupt change from fever to hypothermia with sweating and prostration 
(Rigau-Perez et al., 1998). Shock results from fluid leakage into the interstitial 
spaces, and may be fatal in the absence of  appropriate and immediate treatment 
(Clyde et al., 2006). Prognosis depends on prevention or early detection and 
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management of shock, as fatality rate increases to as much as 12-44% once 
shock occurs (Nimmannitya, 1987). 
 
The risk of developing severe dengue disease is significantly increased in 
individuals who had previously been infected with another DENV serotype 
(secondary infection) (Burke et al., 1988).  
 
2.3.4 Other disease manifestations 
 
In rare cases, DENV-infected individuals exhibit symptoms described as DF 
with massive hemorrhage, liver damage, organ failure, cardiomyopathy, 
encephalopathy, and viral encephalitis (Lum et al., 1996; Nimmannitya, 1987; 
Nimmannitya et al., 1987; Rigau-Perez et al., 1998; Thisyakorn and Thisyakorn, 
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2.4  Dengue Diagnosis 
  
2.4.1 Diagnostic tools  
 
 
Often, clinical symptoms are too diffuse for accurate dengue diagnosis. 
Clinical tests which aid diagnosis include a complete blood cell count (CBC), 
particularly measurements of white blood cells, platelets, and haematocrit levels. 
Other diagnostic tools are tests for albumin, liver function, and urine tests 
(http://www.cdc.gov/). Basic serologic and dengue-specific tests are normally 
employed to verify suspected dengue infections (Gubler, 1998). To detect the 
virus, blood samples during the acute phase must be tested by PCR. Direct virus 
isolation, propagation using mosquito cell cultures or mosquito inoculation can 
identify the infecting DENV serotype using RT-PCR. ELISA is a fundamental 
serologic test to detect anti-DENV neutralizing IgM antibodies 
(http://www.cdc.gov/; Gubler, 1998) early after infection. Due to the low sensitivity 
of the ELISA, dengue infection has to be confirmed with detection of anti-dengue 
IgG in paired samples. The IgG test must show an increase in titer within three 
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2.4.2 The WHO Classification Scheme 
 
In addition to dengue case definition, dengue cases are classified based 
on disease manifestations (Bandyopadhyay et al., 2006; WHO, 1997). The WHO 
guidelines propose that DHF must fulfill the following four criteria: (1) Fever or 
history of acute fever lasting 2 to 7 days, (2) hemorrhagic tendencies with 
evidence of at least one of the following: a positive tourniquet test, petechia, 
purpura, ecchymoses, bleeding from mucosa, gastrointestinal tract, injection 
sites or other location, haematemesis, melena (“tarry" feces that are associated 
with gastrointestinal hemorrhage), (3) thrombocytopenia (≤100,000 platelets/μl) 
or (4) ≥20% rise of hematocrit relative to the normal baseline or evidence of 
plasma leakage (e.g. pleural effusion or ascites) (Bandyopadhyay et al., 2006; 
WHO, 1997).  
 
DHF is further classified into four grades of severity (I-IV). DHF I is only 
defined by a positive tourniquet test. DHF II is characterized by spontaneous 
bleeding in the skin, the nose, or in the internal organs. DHF III patients show 
hypotension, narrow pulse pressure, restlessness, as well as rapid weak pulse, 
whereas those with DHF IV exhibit profound shock with undetectable blood 
pressure or pulse. Individuals with DHF grades III and IV are considered DSS 
cases (Bandyopadhyay et al., 2006; WHO, 1997).  
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The description of severity was based on clinical data from Thai children 
(Cohen and Halstead, 1966). However, global expansion and changing 
epidemiology of the disease led to difficulties in following the old WHO guidelines 
and the demand for reassessment of these guidelines. While WHO 
recommendations from 1997 for case management resulted in the decline of 
dengue fatality rate, the WHO guidelines were inadequate in some ways. These 
guidelines did not properly address overlaps between DF, DHF and DSS 
because of the strict definition of the three disease manifestations.  In many 
severe cases, only one manifestation was observed, which did not fulfill all four 
criteria for DHF/DSS based on WHO guidelines. Additionally, the term dengue 
haemorrhagic fever is confusing because plasma leakage is the life-threatening 
condition that needs utmost attention (Deen et al., 2006). Moreover, the WHO 
classification scheme was often misquoted and entails different and repeated 
clinical tests, which might be a serious hurdle in countries with limited resources 
(Rigau-Perez, 2006). This underscores the need for an improved and universal 
classification scheme. A new edition of WHO guidelines for diagnosis and 
treatment was released in 2009 
(http://whqlibdoc.who.int/publications/2009/9789241547871_eng.pdf). Dengue 
cases are classified into: dengue with or without warning signs (abdominal pain, 
persistent vomiting, clinical fluid accumulation, mucosal bleed, lethargy, 
restlessness, liver enlargement, increase in hematocrit) and severe dengue. 
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2.5 Early events in the host after DENV Infection 
 
Despite significant advances in the understanding of important aspects of 
DENV biology such as structural and functional elucidation of viral proteins and 
analysis of replication and translation mechanisms, very little is know about 
factors contributing to pathogenesis of DENV infection. Incomplete 
understanding of the mechanisms of dengue pathogenesis are partly due to the 
lack of both in vitro and in vivo animal disease models and the complicated 
interplay of viral and host factors. 
 
The bite of an infected mosquito inoculates DENV into the skin. Infection 
is suggested to begin with the interaction of DENV with skin-resident dendritic 
cells (DCs) called Langerhans cells (Wu et al., 2000). They can bind 
glycoproteins of all four DENV serotype via a mannose-specific C-type lectin 
receptor called DC-SIGN (dendritic cell-specific intercellular adhesion molecule 
(ICAM)-3-grabbing non-integrin) (Navarro-Sanchez et al., 2003; Tassaneetrithep 
et al., 2003), which was shown to facilitate DENV entry into the cell 
(Tassaneetrithep et al., 2003). Langerhans cells and other skin-derived dendritic 
cells may migrate to regional lymph nodes via the lymphatic system and 
disseminate DENV to T lymphocytes, blood, kidney, liver, and spleen (Wu et al., 
2000; Jessie et al., 2004). More recently, Lozach et al. (2005) observed that 
Langerhans cells are not readily infected by DENV, whereas DCs are. It is 
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proposed that DC-SIGN just concentrates DENV on the cell surface and a 
hitherto unknown co-receptor may be responsible for virus uptake (Lozach et al., 
2005). 
 
Besides dendritic cells, dengue virus was detected in vivo primarily in 
monocytes, and macrophages (Jessie et al., 2004; Durbin et al., 2008). The virus 
replicates within the first 24 hours of infection. During viral replication, transiently-
generated double-stranded RNAs are recognized by RIG-I and MDA-5 which 
activate type-I interferon signaling (Cheng et al., 2006; Green and Rothman, 
2006; Loo et al., 2008). The infection of DCs results in their activation and 
maturation, including neighboring DCs, leading to the secretion of the cytokines 
IFN-α, IL-10, TNF-α (Green and Rothman, 2006). IFN-α and TNF-α boost 
complement activation and C3a and C5a production, which may have a major 
impact on vascular permeability, and consequently on disease outcome (Lei et 
al., 2001; Navarro-Sanchez et al., 2005). DENV can reduce the host antiviral 
response by inhibiting Type I interferon (IFN alpha and IFN beta) signaling by 
suppressing Jak-Stat activation (Munoz-Jordan et al., 2003). Infected DCs 
migrate to the lymph nodes but their ability to stimulate T-cells is impaired. 
Neighboring DCs that have been concomitantly activated and underwent 
maturation may be responsible for activating the adaptive immune response 
(Green and Rothman, 2006). 
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Cytokines and chemokines released by DCs and macrophages contribute 
to clearance of DENV-infected cells by natural killer (NK) cells via direct 
cytotoxicity or by antibody-dependent cell-mediated cytotoxicity (ADCC) 
(Navarro-Sanchez et al., 2005).  Nitric oxide produced by IFN-γ-activated 
macrophages has recently been demonstrated to inhibit DENV replication in vitro 
(Charnsilpa et al., 2005). Overproduction of NO, however, may augment vascular 
permeability.  Basophils, mast cells, and neutrophils are important cellular 
components of innate immunity that may play a role during DENV infection, but 
how these cells contribute to protection or pathology remains to be clarified. 
Granulocytes interact with endothelial cells, which might explain neutropenia and 
thrombocytopenia in DHF patients (Butthep et al., 1993). The absolute number of 
leukocytes is decreased during DENV infection, which may be a result of cell 
death or accumulation in the tissue (Azeredo et al., 2001). 
 
2.6  Risk Factors for Severe Disease 
 
The broad range of symptoms in dengue infections may reflect multiple 
mechanisms of pathogenesis. The risk of developing DHF/DSS is increased in 
patients who experience a secondary DENV infection with a serotype different 
from that of the primary infection (Halstead, 1988). The occurrence of primary 
infections developing into severe diseases suggests a role for viral and host 
factors and their complex interactions in pathogenesis. 
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2.6.1  Viral Factors 
 
2.6.1.1  Viral Serotype  
 
Distinct DENV serotypes may present varying risk factors to pathogenesis. 
In Nicaragua, comparison of two time periods of dengue infections (when DENV-
2 predominated and when majority of the viruses identified was DENV-1) 
revealed that a higher extent of vascular permeability, more hospitalized primary 
dengue cases, and more primary infections with severe symptoms have been 
linked to DENV-1 period than during DENV-2 outbreak. DENV-2 was associated 
with more internal hemorrhage and shock (Balmaseda et al., 2006).  
 
2.6.1.2 Viral Genotype  
 
By correlating epidemics with certain DENV genotypes, molecular 
epidemiological studies suggest a role for viral genetics in DHF. One nice 
example comes from South America. Nucleotide sequence comparisons from the 
E/NS1 regions of DENV genome revealed that the replacement of the native 
American genotype which had only been linked to DF by the imported DENV-2 
Southeast Asian genotype correlated with the emergence and spread of DHF in 
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Brazil, Colombia, Mexico, and Venezuela (Rico-Hesse, et al., 1997). 
Phylogenetic analysis of isolates of DENV-3, subtype III from mild and severe 
outbreaks formed distinct genetic clusters. This DENV-3 genotype originated in 
India and spread to and caused DHF epidemics in Latin America, East Africa, 
and Sri Lanka (Messer, et al., 2003).  
 
2.6.1.3 Genetic Determinants of Virulence 
 
Attempts to find specific genetic determinants of virulence have identified 
molecular markers of attenuation, nucleotide sequence alterations in regions of 
the DENV genome that changed virulence. Kawano et al. (1993) mapped most of 
the genetic loci encoding neurovirulence of mouse-adapted DENV4 mutant within 
the structural protein genes. Amino acid differences in the E glycoprotein were 
shown to be very important determinants of neurovirulence in mouse and that the 
loss of glycosylation site in the E protein may have a role to play the in 
neurovirulence of DENV4 (Kawano et al. 1993). Mutations in the 5‟ non-coding 
region (NCR) have been shown to limit virus growth (Kinney et al., 1997). 
Furthermore, DENV4 mutants with deletions upstream of the 3‟ non-coding 
region (NCR) had reduced infectivity in simian LLC-MK2 cells relative to the wild-
type parental virus (Men et al., 1996). Mangada and Igarashi (1997) determined 
3‟ NCR of DENV2 specific for each of the viruses isolated from dengue patients 
with different clinical severities. A DENV2 isolate from a dengue fever cases 
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showed the highest nucleotide sequence divergence from the DENV2 New 
Guinea C prototype strain at the 3‟ NCR, whereas isolates from severe dengue 
cases were more closely related to the prototype at this region of the DENV 
genome (Mangada and Igarashi, 1997). It was shown that the 3‟ NCR of the 
isolate from the mild dengue case contains significant structural dissimilarities 
from severe dengue isolates (Mangada and Igarashi, 1997). Studies by Mangada 
and Igarashi (1998) on new  DENV2 strains from DF, DHF, and DSS patients 
further identified sites in the 3‟ NCR that contribute to virulence. It is thought that 
permutations of sites across the viral genome may determine the infectious 
capabilities of DENV strains.  
 




Based on secondary DENV-2 infections, a high death rate was observed 
among children aged 3-4 years in a DHF/DSS outbreak in Cuba. Death rate 
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2.6.2.2 Genetic factors 
 
While individuals who have had a previous DENV infection are at higher 
risk of developing DHF, not all individuals who experience secondary infections 
with a different DENV serotype develop severe symptoms (Burke et al., 1988). 
Likewise, primary infections can be as severe as secondary infections. Host 
genetic background may also contribute to predisposition or resistance to severe 
dengue. 
 
In Cuba, a retrospective seroepedemiologic study of DHF showed that 
severe disease was more common in dengue-infected white people than in black 
people (Guzman, et al., 1990). DHF had not been recorded in Haiti despite 
DENV transmission rates similar to those in countries endemic for DHF. Almost 
85% of the 210 school children tested had antibodies against two or more DENV 
serotypes. The DENV 2 isolates in this country were of genotype I, which is 
frequently implicated in DHF in the Americas and Southeast Asia (Halstead et al, 
2001). Thus, in certain populations,  genes that confer resistance or susceptibility 
to dengue may exist. 
 
A case-control study of DHF patients in Vietnam showed significant 
association of HLA-A locus variation and predisposition to DHF and discovered 
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resistance and susceptibility alleles (Loke et al., 2001). Polymorphisms at the Fcγ 
receptor and vitamin D receptor (VDR) loci had also been linked with 
susceptibility to DHF (Loke et al., 2002). More recently, variation in genes 
encoding transporters associated with antigen-presentation (TAP) were linked to 
resistance or susceptibility to DHF (Soundravally and Hoti, 2007). 
 
Previous studies have correlated polymorphisms in HLA class I, TNF-α 
and Fcγ receptor IIA genes (Chiewsilp et al., 1981, Fernandez-Mestre et al., 
2004, Loke et al., 2001, Stephens et al., 2002) with DHF. CD209 (Sakuntabhai et 
al., 2005) and some HLA alleles were linked to the risk of DF rather than DHF.  
 
Secondary infection, host susceptibility, or viral factors cannot account for 
dengue pathogenesis on their own, though. There is general consensus that 
intricate connections of epidemiological factors (high vector density, high virus 
circulation, a population at risk of a secondary DENV infection), host factors (age, 
gender, ethnicity, chronic diseases, pre-existence of DENV antibodies, interval 
between infections, and genetics), and viral factors (serotype, strains, and 
genotypes) most likely contributes to the risk of infection and disease severity 
(Bravo et al., 1987, Kouri et al., 1987). 
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2.7  Protective Immune Responses After Dengue Infection 
 
2.7.1   Innate immune response 
 
2.7.1.1 Dendritic cells 
 
The innate arm of the host immune system is responsible to limit infection 
during the acute phase and most likely determines the outcome of disease. 
Immature dendritic cells (iDCs) may play a role in defense against DENV in the 
early phase of infection. They are widely distributed in peripheral tissues, thus at 
possible sites of pathogen entry. They sense the antigenic environment as 
sentinels and capture antigens (Navarro-Sanchez et al., 2005). In humans, at 
least four DC types have been described: CD14+ blood, monocyte-derived DCs 
(moDCs), CD34+ hematopoietic progenitor cell (HPC)-derived dermal or 
interstitial DCs (DDC-IDCs), CD34+ HPC-derived Langerhans cells (LCs), and 
plasmacytoid DCs (PDcs) (Liu, 2001). Amongst DCs, PDCs are the most efficient 
producers of IFN-α, making them potent antiviral (effector) cells. Together with 
blood-precursor myeloid DCs (pre-moDCs), PDCs defend the host against 
viruses and shape Th1 responses. IFN-α released by DCs can induce activation 
of other DCs (Navarro-Sanchez et al., 2005). DCs have been shown to play a 
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major role in activating NK cells (Bottino et al., 2004; Ferlazzo et al., 2002; 
Piccioli et al., 2002), which are important components of innate immunity.  
 
2.7.1.2 Natural killer cells 
 
NK cells belong to a separate subset of bone marrow-derived lymphoid 
cells which function in innate immune defense (Cerwenka and Lanier, 2001). 
They comprise about 5-10% of all lymphocytes and make up 10-15% of human 
PBMC (Robertson and Ritz, 1990), representing the principal lymphoid cell 
population that participates in innate immune functions. As such, NK cells serve 
as a first line of defense against a broad spectrum of pathogens including viruses 
by clearing the virus during acute infections, long before the activation of 
adaptive immune responses (Trinchieri, 1989). Activated NK cells do so by 
cytotoxic granule-mediated killing of virus-infected cells or lysis of antibody-
coated cells (antibody-dependent cell-mediated cytotoxicity; ADCC). They also 
respond to infection indirectly by interacting with DCs (Lodoen and Lanier, 2006). 
 
 Human NK cells are defined by the lack of CD3 and the expression of 
CD56, the neural cell adhesion molecule (NCAM) 140 kDa isoform (Lanier et al., 
1989; Moretta et al., 1989). Circulating NK cells can be activated by cytokines or 
upon encounter with target cells expressing ligands of NK cell receptors (Lanier 
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2005). NK cell receptors, which do not undergo somatic recombination (as TCRs 
and BCRs do), belong to two families: the killer Ig-like receptors (KIRs) and 
CD94NNG2A. The former are members of the immunoglobulin superfamily and 
are class I HLA (HLA-A, -B, -C)-specific receptors, while the latter family 
specificcaly recognizes HLA-E (Yokoyama et al., 2004; Moretta et al., 2004). The 
outcome of NK cell activity is finely regulated by the balance of signals from 
activating and inhibitory NK receptors. Activating receptors recognize and bind to 
ligands derived from the host or pathogen, which are expressed on infected or 
stressed cells. A number of inhibitory NK receptors are specific for class I MHC 
expressed on all uninfected nucleated cells, preventing NK cell from attacking 
healthy cells (Lodoen and Lanier, 2006). 
 
Chemokines secreted by virus-infected cells and activated tissue-resident 
macrophages allow the rapid recruitment of NK cells to sites of infection. NK cells 
proliferate in response to IFN-α/β produced by activated macrophages. IFN-α/β-
induced NK cell activation leads to the identification and killing of antibody-coated 
cells (antibody-dependent cell-mediated cytotoxicity via CD16 and CD56), virus-
infected cells (by releasing perforin- and granzyme-containing granules), and 
those that do not express the correct MHC molecules; and secretion of antiviral 
cytokines (IFN-γ and TNF-α) and chemokines.  IFN-γ produced by NK cells 
stimulates DCs and macrophages and directs Th1 adaptive immune responses 
(Robertson, 2002; Degli-Esposti and Smyth, 2005; Lodoen and Lanier, 2006).   
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Reports on the role of NK cells in dengue infection are limited. A study on 
primary DENV infection in mice suggested that early activation of NK cells is 
likely to be important in DENV clearance (Shresta et al., 2004). Azeredo and co-
workers (Azeredo et al., 2005) observed low percentage of NK cells in dengue 
patients and the lack of CD69 expression (comparable to healthy individuals) 
was linked with severe disease, whereas increased frequencies of NK cells and 
of activated (CD69+) NK cells seemed to be protective. These observations 
highlight a hitherto unknown important role that NK cells play during dengue 
infection. The potential of NK cells as frontliners in anti-DENV defense and the 
limited number of reports to elucidate their role during dengue infection highlight 
the need for further studies.  
 
2.7.1.3 T Lymphocytes expressing CD56 
 
Human T lymphocytes that express CD56 belong to a heterogeneous 
group of T cells that includes CD4+, CD8+, and CD4-CD8- cells expressing 
MHC-or CD1d-restricted (classical NKT cells whose invariant TCR recognizes 
glycolipid antigens) TCRs. These cells also express assorted permutations of NK 
cell receptors (Ortaldo et al., 1991; Ohkawa et al., 2001).  
 
CD56-expressing T cells demonstrate dual innate and adaptive immune 
functions, having features of both NK cells and T cells. They have been shown to 
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kill tumor cells via MHC-unrestricted perforin/granzyme-mediated cytolysis 
without prior antigenic exposure (Ortaldo et al., 1991; Pittet et al., 2000). The NK-
like cytotoxic capability of these cells seems to be mediated by cytokine 
exposure and activated by antigen-nonspecific stimulatory NKR ligation and/or 
TCR ligation (Kelly-Rogers et al., 2006). These cells also secrete IFN-γ, TNF-α, 
and IL-4 and display T cell-like cytotoxic activities restricted by MHC or CD1d 
and mediated by TCR (Ortaldo et al., 1991; Jin et al., 1998; Doherty et al., 1999; 
Ohkawa et al., 2001). 
 
Such “innate lymphocytes” displaying innate and adaptive functional 
phenotypes could serve as the first line of defense against a broad spectrum of 
infectious agents including viruses and could potentially regulate adaptive 
immunity against these pathogens. Such roles in the body could be underscored 
by the phenotypic changes and quantitative and functional deficiencies of CD56-
expressing T cells observed in hepatitis B (Barnaba et al., 1994), hepatitis C 
(Deignan et al., 2002) and HIV (Tarazona et al., 2002) viral infections.   
 
Classical NKT cells recognize lipid antigens presented by DCs on CD1 
molecules. They are a subset of immunoregulatory T cells that coexpress NK cell 
markers such as CD56 and/or CD 161 and T cell receptors (TCRs) (Godfrey et 
al., 2000). Among these are the CD1d-dependent NKT cells, restricted by the 
MHC class I-like, glycolipid antigen-presenting molecule CD1d. CD1d-reactive 
NKT cells expressing invariant TCR α-chain rearrangement and Vβ chains are 
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referred to as invariant NKT (iNKT) cells (Durante-Mangoni et al., 2004). They 
have a greatly biased T cell receptor repertoire, where more than 80% of NKT 
cells express an invariant alpha chain Vα24JαQ, and mostly express the TCR 
beta chain Vβ11  (Crowe et al., 2003). They are stimulated by the marine 
sponge-derived α-galactosyl ceramide (α-GalCer). Although endogenous 
glycolipid antigens remain to be discovered, glycolipids related to α-GalCer 
probably induce iNKT cells under a variety of disease states (Durante-Mangoni et 
al., 2004). On the other hand, CD1d-independent NKT cells do not rely on CD1d 
for their activity and express unbiased TCR-αβ repertoire. 
 
Depending on anatomical origin and health conditions of the donor, NKT 
cells quickly produce huge quantities of Th1 and/or Th2 cytokines, and hence 
initiate and direct immune responses. Activated NKT cells rapidly produce 
cytokines that boost the activity of NK cells, dendritic cells, B lymphocytes, and 
conventional T lymphocytes (Galli et al., 2003; Gillesen et al., 2003; Nishimura et 
al., 2000; Carnaud et al.,1999; Tomura et al., 1999), and have been implicated in 
a number of inflammatory diseases. They also exhibit CD1d-specific cytotoxic 
activity (Metelitsa et al., 2001).  
 
 Studies in mice have demonstrated a protective role for NKT cells against 
a broad range of infections, including viruses (Godfrey et al., 2000; Kronenberg 
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and Gapin, 2002). They have been implicated in protection against some 
infectious agents such as encephalomyocarditis virus (Exley et al., 2001), 
Pseudomonas aeruginosa (Nieuwenhuis et al., 2002), and respiratory syncytial 
virus (Johnson et al., 2002). In addition, impaired clearance of herpes simplex 
virus type 1 was observed in mice lacking CD1d or NKT cells (Grubor-Bauk et al., 
2003), while the vaccine strain Varicella zoster virus caused Varicella infecion in 
an NKT cell-deficient patient (Levy et al., 2003). NKT cells with defective cytokine 
secretion have been linked to the inability to eliminate infectious agents and 
tumors in humans and mice (Brigl and Brenner, 2004; Kronenberg, 2005). NKT 
cells can stimulate DCs (Gillessen et al., 2003; Kitamura et al., 1999), APCs 
(Tomura et al., 1999), B cells (Galli et al., 2003), CTLs (Nishimura et al., 2000), 
and NK cells (Carnaud et al., 1999).  
 
 The role of CD56-expressing T lymphocytes in dengue infection has not 
been extensively studied. Thus far, the only report that investigated CD56+CD3+ 
lymphocytes in dengue infection was that by Azeredo and co-workers (Azeredo 
et al., 2005). They observed the increase in the frequency of CD69+ 
CD56+CD3+ cells during the acute phase of infection. They also reported that 
majority of these cells also expressed the early activation markers CD38 and 
HLA-DR and the cell adhesion molecules CD11a and CD44 (Azeredo et al., 
2005), 
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The paucity of studies investigating the role of CD56+ T lymphocytes in 
dengue infection and the potential of these cells as frontliners in anti-DENV 
defense and in regulating adaptive immunity against DENV underscores the 
need for further studies of the involvement of CD56+ T cells during dengue 
infection. The increased frequency and early activation of these cells and its 
association with mild dengue disease as reported by Azeredo et al. (2005) 
highlights a hitherto unknown important role that these cells play during dengue 





In vitro and in vivo studies illustrate the protective role of interferons 
against DENV. Treatment of cells with IFNs (IFNα/β/, IFN-γ) before DENV 
infection protects cells against the virus by preventing DENV RNA translation, 
hence viral replication (Diamond et al., 2000; Diamond et al., 2001; Ho et al., 
2005) IFN –α, -β, and -γ-receptor-deficient mice were shown to allow much 
higher levels of DENV replication and are more vulnerable to disease (Shresta et 
al., 2004; Johnson and Roehrig, 1999)   A study in mice associated both STAT1-
independent and STAT1-dependent pathways in IFN-mediated control of DENV 
infection (Shresta et al., 2005). DENV suppresses activation of the JAK-STAT 
pathway, thereby inhibiting the antiviral IFN response (Munoz-Jordan et al., 
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2003), underscoring the importance of IFN signaling during DENV infection. 
Serum from patients with DF and DHF had substantially higher levels of IFNα 
and IFN-γ than healthy individuals, and higher levels in severe dengue cases 
than in DF patients (Kurane et al., 1993; Kurane et al., 1991; Libraty et al., 2002; 
Chakravarti and Kumaria, 2006). DF and DHF patients who survived infection 
had significantly higher levels of IFN-γ than healthy individuals, in contrast to 
nonsurvivors (Chen et al., 2006) Furthermore, microarray studies on whole blood 
of DHF patients revealed upregulation of several IFN-activated genes, while 
those with DSS had significantly less abundant transcripts of the same genes 
(Simmons et al., 2007), signifying that the weakening of type I IFN responses is 
linked to the development of DSS. Nevertheless, the effectiveness of IFN therapy 
for the treatment of dengue infections has yet to be demonstrated.  
 
2.7.2 Adaptive immune responses 
2.7.2.1 Antibody-mediated protective immunity 
 
 Studies in animals demonstrate that humoral immunity may be important 
to control the spread of DENV. Multiple protective mechanisms of antibodies 
against flaviviruses are possible: prevention of binding to cell receptors, inhibition 
of viral fusion, Fcγ-receptor-mediated viral clearance, antibody-dependent cell 
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cytotoxicity of infected cells, and complement-mediated lysis of infected cells or 
virus (Pierson et al., 2008). 
 
   DENV E-glycoprotein is a major target of neutralizing antibodies. Mouse 
monoclonal antibodies (MAbs) raised against the E glycoprotein of DENV-2 can 
neutralize viral infectivity and block DENV binding and fusion (Roehrig et al., 
1998).  Passively transferred monoclonal antibodies protected mice against lethal 
intracerebral dengue infection (Kaufman et al., 1987). In vitro, chimpanzee anti-
DENV-4 MAb can neutralize the virus at a high titer (Lai et al., 2007). A variant of 
the humanized version of this chimpanzee MAb was shown to passively protect 
mice and monkeys against DENV-4 challenge (Lai et al., 2007) without causing 
antibody-dependent enhancement of disease (ADE). This variant MAb contains a 
nine-amino-acid deletion in the Fc region that completely removed the ADE 
potential of the antibody in vitro (Lai et al., 2007). 
 
Aside from anti-E protein antibodies, anti-NS1 protein and anti-prM protein 
antibodies have also been demonstrated to protect mice against lethal DENV 
infection. Passively transferred murine anti-DENV3 and DENV4 prM MAbs 
protected mice against lethal homologous and heterologous DENV infection and 
could fix complement (Kaufman et al., 1989). In another study, anti-NS1 
antibodies mediated the lysis of DENV-infected cells via complement, and 
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provided passive protection against homologous but not heterologous DENV 
intracerebral challenge (Schlesinger et al., 1987). 
 
It has been shown that neutralizing antibody levels below a neutralizing titer, 
as well as antibodies binding to non-neutralizing epitopes, promote antibody-
dependent enhancement of infection in vitro in human monocytes and monocyte 
cell lines (Morens and Halstead, 1990). A recent study demonstrated that 
depending on complement level, a single antibody can be neutralizing or 
infection-enhancing, suggesting a role for complement in determining disease 
severity (Yamanaka et al., 2008).  
 
2.7.2.2 T cell-mediated protective immunity 
  
As with other viral infections, T cell responses are crucial after DENV 
infection. Still, there is limited published information on the contribution of DENV-
specific T cell responses to long-term protective immunity or 
immunopathogenesis.  
 
 While most DENV viral proteins are targets of T cell responses, the non-
structural protein NS3 appears to be the most immunogenic. Most of the CD4+ 
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and CD8+ T cell epitopes identified lie in the NS3 protein (Kurane et al., 1991; 
Lobigs et al., 1994; Mathew et al., 1996; Appanna et al., 2007).  
 
DENV-infected antigen-presenting cells interact with and activate DENV-
specific CD4+ and CD8+ T cells. Activated T cells proliferate and produce high 
levels of IFNγ, TNF-α, TNF-β, and MIP-1β. They can also efficiently kill DENV-
infected cells by granzyme and perforin-mediated lysis (Gagnon et al., 1999; 
Rothman et al.,2003).  
 
Mangada et al. (2002) showed a weak correlation of DENV-specific, 
serotype cross-reactive IFNγ T cell responses with mild dengue in PBMCs from 
DENV-immune school children before secondary DENV infection. An 
investigation on PBMCs of individuals who received live attenuated monovalent 
DENV vaccine, Mangada and Rothman (2005) revealed higher percentages of 
CD4+ than CD8+ T cells that produced IFNγ in response to homologous 
stimulation with whole DENV antigen. In contrast, heterologous antigen 
stimulation led to higher frequencies of TNFα-producing T cells (Mangada and 
Rothman, 2005). These results indicate that among the heterogeneous DENV-
specific T cell pool, different functional T cell subsets are present and that their 
activities may contribute to positive prognosis.  
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2.8 Immunopathogenesis  
 
It has been hypothesized that severe dengue may be caused by the 
patients‟ immune system (Halstead, 1988) as it responds to the virus. Primary 
dengue infection generates serotype cross-reactive antibodies and T-
lymphocytes, which are reactivated and may contribute to immunopathology 
(Zivny et al., 1999). 
 
Immunopathology comprises an intricate chain of immune events initiated 
by infection with a virulent serotype. During secondary infection, infection-
enhancing antibodies exacerbate infection with the virus. Immune responses are 
highly activated, resulting in elevated levels cytokines and chemical mediators 
that induce hemorrhage, plasma leakage, and shock.  
 
2.8.1 Antibody-mediated pathogenesis: the antibody-dependent enhancement 
hypothesis 
 
  Infection with one DENV serotype provides lifelong immunity against the 
same serotype but not against other serotypes. Sequential heterotypic infection 
has been shown to enhance virus replication, hence the likelihood to develop 
DHF. Antibody-dependent enhancement (ADE) is widely believed to contribute to 
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the development of severe dengue manifestations. This phenomenon has been 
described for various viral infections, including those caused by flaviviruses like 
JEV and WNV (Porterfield, 1986). 
 
In vitro, DENV infection of mast cells can result in the selective release of 
cytokines IL-1β and IL-6 (King et al., 2000) and chemokines CCL3 (human 
macrophage inflammatory protein alpha or MIP-1α), CCL4 (MIP-1β), and CCL5 
(Regulated on Activation Normal T-cell Expressed and Secreted or RANTES) 
(King, et al., 2002). IL-1β and IL-6 are strong vasoactive cytokines (King et al., 
2000) that could contribute to vascular permeability and microvascular leakage in 
DHF and DSS. IL-6 has a fever-inducing (pyrogenic) property (Helle, 1988) and 
was demonstrated to enhance permeability of endothelial cells (Maruo et al., 
1992).  
 
On the other hand, CCL3, CCL4, and CCL5 are T-cell chemoattractants. 
CCL4 attracts helper T-cells, preferably CD45RA+ or naïve T-lymphocytes. CCL3 
is a strong lymphocyte chemoattractant, primarily for cytotoxic T-lymphocytes 
and B-lymphocytes (Schall, et al., 1993). CCL5 had been shown to effect the 
migration of memory helper T-cells (CD4+UCHL1+) and of monocytes (Schall, et 
al., 1990). Antibody-enhanced mast cells and basophils are suggested to provide 
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these chemokines to recruit immune effector cells during DENV infection (King, 
et al., 2002).  
 
2.8.2 T cell-mediated pathology 
 
2.8.2.1 T cell activation 
 
It has been observed that the magnitude of Th cell and CTL activation in 
DHF patients exceeds that in individuals with DF (Rothman and Ennis, 1999; 
Rothman, 2003). Higher levels of soluble CD8 were observed in serum of Thai 
children afflicted with DHF than in children with DF (Kurane et al., 1991), 
suggesting that CTLs are more activated in DHF but not in DF. Other indicators 
of T cell activation associated with DHF are higher levels of soluble IL-2 receptor, 
soluble CD8, soluble TNF receptors (Green et al., 1999b), and TNF-α (Hober et 
al., 1993; Mangada et al., 2003), and earlier peak levels of IFN-γ (Libraty et al., 
2002).  
 
After viral replication in monocytes and macrophages, DENV antigens are 
presented on cell surface human leukocyte antigens (HLA) of these cells to Th 
cells and CTLs. DENV antigen-specific memory Th cells and CTLs generated 
during a previous infection are activated, proliferate, and release IFN- γ and TNF-
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α (Mangada et al., 2002), which may cause vascular permeability by acting on 
vascular endothelium, leading to plasma leakage.  
 
T cells activated by infected, functionally-impaired antigen-presenting cells, 
may undergo apoptosis (Mathew et al.,1999; Myint et al.,2006). High degree of 
T-cell activation, with concomitant massive apoptosis, had been documented in 
children with severe dengue (Mongkolsapaya et al., 2003).  
 
Alternatively, DENV-infected macrophages stimulate Th cells to secrete a 
unique, hitherto uncharacterized cytokine called human cytotoxic factor (hCF), 
which induces macrophages to produce free radicals, reactive oxygen, nitrite, 
and peroxynitrite.  (Chaturvedi et al., 2000). These free radicals promote 
apoptosis in target cells, leading to a shift from Th1 to Th2 responses. The 
effects of pro-inflammatory cytokines together with those of free radicals and 
histamines may result in enhanced vascular permeability, hence severe disease 
(Stephenson, 2005). Nonetheless, elevated levels of these cytokines are 
observed in other infectious diseases without causing enhanced vascular 
permeability (Stephenson, 2005). 
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2.8.2.2 T-cell original antigenic sin: the role of serotype cross-reactive DENV-
specific T cells 
 
Cross-reactive antibodies and ADE may not solely account for the 
increased frequency of severe disease in secondary dengue infections. Cross-
reactive dengue-specific CTLs generated during primary infections, which could 
be activated during secondary virus challenge, have been detected in mice 
(Spaulding et al., 1999) and humans (Mathew et al., 1998). The presence of 
these serotype cross-reactive T cells in patient PBMCs after primary DENV 
infection indicates that memory T cells may have a role in the pathology of 
severe dengue. 
 
DHF patients in Vietnam had high frequencies of circulating CTLs (Loke et 
al., 2001). Using ELISPOT and tetramers to identify epitope-specific T cell 
responses showed the association of higher frequencies of epitope-specific T 
cells and severe disease (Zivna et al., 2002; Mongkolsapaya et al., 2003; 
Mongkolsapaya et al., 2006).  
 
Serotype cross-reactive T cells derived from the clonal expansion of 
memory CTLs generated during primary infection have lower activation threshold 
than do naïve CTLs, with quicker and more active responses (Veiga-Fernandes 
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et al., 2000), hence their preferential expansion early during heterologous 
secondary immune responses. These cells are partially activated by variant 
heterologous T cell epitopes, resulting in suboptimal antiviral effect but enhanced 
output of proinflammatory cytokines, thus the poor clearance of the virus and 
severe disease outcomes (Kurane et al., 1994; Zivny, et al., 1999). Memory 
CTLs have been suggested to stimulate production of high levels of vasoactive 
cytokines that augment vascular permeability and lead to the development of 
DHF during secondary infection (Mongkolsapaya et al., 2006).  
 
The nature of altered secondary T cell immune responses has been the 
subject of a number of studies. Analyses of cross-reactivity patterns of CTL 
responses to DENV identified mostly primary infection-induced CTLs that cross-
react with low affinity for the secondary infecting serotype, hence the insufficient 
immune response (Zivny et al., 1999; Mongkolsapaya et al., 2003). Instead, 
these serotype cross-reactive T cells had higher affinity for strains encountered 
earlier. The higher precursor frequency of these cells, or the activation-induced 
cell death of high affinity T cells may result in a secondary response dominated 
by low affinity memory T cells. Based on these observations, the term „original 
antigenic sin‟ was introduced by Mongkolsapaya et al. (2003). This observation 
resembles the phenomenon of „original antigenic sin‟. The term was first used to 
describe antibody response to a secondary infection governed by the stimulation 
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of cross-reactive memory B cells generated by the primary virus challenge with a 
different serotype (Fazekas and Webster, 1966).  
 
Original antigenic sin in T cell responses could contribute to pathology of 
severe dengue in two ways. Low affinity of T cells to the currently infecting 
heterologous serotype suppresses elimination of the virus, leading to higher viral 
loads.  Partial activation of these cells by heterologous T cell epitopes  results in 
increased proinflammatory response. DENV-specific CTLs from children with 
DHF have low binding affinity for the infecting DENV serotype and failed to clear 
the infection (Mongkolsapaya et al., 2003). 
 
Taken together, enhanced T-cell activation, massive apoptosis, and 
cellular immune responses dominated by low binding affinity cross-reactive T-
cells could impede virus clearance, resulting in high viremia titer and increased 
immunopathology (Stephenson, 2005). An individual‟s infection history influences 
the outcome of a secondary infection with a heterologous DENV serotype. 
Secondary infection alters serotype cross-reactive memory T cell repertoire, 
preventing efficient viral clearance, which results in increased immune responses. 
Sequential infection by heterologous serotypes provides variant T cell epitopes 
that modify immune responses, giving rise to heterologous immunity.  
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2.9  Dengue in Singapore 
 
A highly effective vector control program implemented since the late 1970‟s 
prevented dengue outbreaks in Singapore. However, dengue has resurged since 
1986 notwithstanding the very low national Aedes house index (Ooi et al., 2001). 
In 2005, dengue cases peaked with 14, 209 laboratory-confirmed cases (Figure 
2.3), an increase of greater than 50% compared to 2004. Most cases were 
reported between the months of June and October, with a weekly incidence of 
over 700 cases in September (Ministry of Health, 2006).  There is an on-going 
campaign against dengue in Singapore and the number of cases is reported 
weekly since 2006 (Figure 2.4; http://www.dengue.gov.sg/).  
 
During the 2005 dengue outbreak, DENV-1 and DENV-3 co-circulated with 
a low degree of DENV-2 transmission and no infection caused by DENV-4 was 
observed (Low et al., 2006). Majority of the DENV-1 genomes fell into genotype I, 
which predominates in Southeast Asia (Schreiber et al., 2009). Most of the 
DENV-3 genomes were classified as genotype III (Schreiber et al., 2009), which 
originated in India and introduced into and caused DHF epidemics in Latin 
America, East Africa, and Sri Lanka (Messer, et al., 2003). Viremia and clinical 
outcomes were different for DENV-1 and DENV-3.  
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Figure 2.4. Dengue cases in Singapore every week between 2006-2008. 
(http://www.dengue.gov.sg/) 
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In Singapore, dengue affects mainly young adults (ages 15-24 years) (Goh, 
1995). Young male adults have the highest risk of being infected. (Ooi et al., 
2003; Ooi et al., 2006). During the 2005 dengue epidemic, the male to female 
ratio was 1.4:1, with the highest incidence found in the age groups between 15 to 
24 years old (Ministry of Health, 2006). The odds ratio of dengue seroprevalence 
increases by 4.13 for every 10 years increase in age (Wilder-Smith et al., 2004). 
The factors for the 2005 outbreak are not fully understood but could include 
lowered herd immunity, increased virus transmission outside the home, and shift 
of emphasis away from surveillance of vector toward the detection of cases (Ooi 
et al., 2006). In addition, adults suffer from symptomatic infections more often 
than children, hence more cases are reported. Additionally, adults may have a 
lower risk of developing DHF/DSS than children possibly due to age-dependent 
vascular permeability differences (Gamble et al., 2000). 
 
Dengue affects mostly children and female adults in other countries in 
Southeast Asia, especially in Thailand and Vietnam (Halstead et al., 2002). In the 
Americas, dengue tends to affect all age groups (Rigau-Perez, 1997). In 
Nicaragua, disease burden and severe dengue predominated in children 
(Hammond et al., 2005). In contrast to the prevalence of pediatric cases in 
Southeast Asian countries, the burden of disease in Singapore was found 
predominantly in young adults (Ooi et al., 2003; Ooi et al., 2006).  
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The shift from DHF/DSS epidemics to that of classic DF had been 
observed over the years. Before the implementation of the highly successful 
mosquito control programs, the disease had a higher prevalence in children, thus 
more cases of DHF/DSS were reported. Although the overall occurrence of 
cases is much higher at present, classic DF cases are more likely to occur than 
DHF/DSS most likely due to the adult age at infection (Ooi et al., 2006). 
 
Dengue infection in young adults rarely results in severe disease (Lye et al., 
2008; Lye et al., 2009) and may thus make hospitalization unnecessary. Safe 
monitoring of patients with acute dengue infection as outpatients will enhance the 
ability of physicians to look after patients with severe dengue who need utmost 
attention. To date, there are no simple clinical and laboratory markers that are 
predictive of severe adverse outcomes, making the identification of these 
predictors of severe dengue of utmost importance.  
 
Dengue has been extensively studied in children, thus most of the present 
knowledge and understanding about the disease information is based on 
pediatric data. Aspects of adult dengue infections including clinical and laboratory 
features, epidemiology, clinical outcomes, and immunology are not well-studied, 
which may differ between children and adults and could thus present new 
challenges in disease management.  
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Viremia and clinical outcomes differed for DENV-1 and DENV-3 that co-
circulated during the 2005 dengue epidemic in Singapore (Low et al., 2006). It is 
proposed that since adaptive evolution of these viruses was not observed before, 
during, and after the outbreak, ecological and/or immunological, instead of 
virological factors, primarily determine the dynamics of DENV in epidemics 
(Schreiber et al., 2009). Since pathogenesis of severe dengue disease is not 
completely understood and strong immune cell activation had been found to 
correlate with severe dengue disease, a better understanding of immune cell 
responses in dengue infection is urgently needed. 
 
The immune responses of adults may differ from that of children. 
Immunological correlates of protection in the context of adult, non-severe dengue 
cases, and a different genetic background can be investigated in the 
Singaporean cohort. Pathology in an otherwise benign case provides a unique 
opportunity for studying a distinct group of individuals with unique case 
presentation. Hence, our results may contribute additional and/or novel 
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2.10  The Early DENgue Infection and Outcomes (EDEN) Study 
 
The EDEN study, initiated during the Singaporean dengue outbreak in 
2005, is a collaborative longitudinal study involving the Tan Tock Seng Hospital 
(TTSH), the Genome Institute of Singapore (GIS), Novartis Institute for Tropical 
Diseases (NITD), the Environmental Health Institute (EHI), the Singapore Tissue 
Network (STN), Defense Science Organization (DSO) National Laboratories, and 
the National Healthcare Group (NHG) Polyclinics. It addresses viral, clinical, 
host-specific, and epidemiological aspects of adults with early dengue infection 
(Low et al., 2006). The study‟s specific objectives are as follows: 
 
1) To identify early markers of the disease that are predictive of outcomes 
such as DF and DHF 
2) To identify pathways that lead to severe disease that may be 
amenable to therapeutic intervention 
3) To study the epidemiological features of adult infection  
4) To develop robust molecular tools for epidemiological investigation 
5) To correlate virulence with virus sequences and their replication 
properties, and 
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6) To refine early dengue clinical and laboratory diagnostic tools (Low et 
al., 2006) 
 
The study recruited 455 adults in 2005 (>21 years) febrile (>38.0 C for 
less than 72 hours) patients without rhinitis or clinically obvious alternative 
diagnoses. On the first visit (1-3 fever days) by the patient, initial blood and saliva 
samples were collected. Those who tested positive in dengue-specific PCR were 
presumed dengue cases.  Blood and saliva samples were also collected on the 
second visit (4-7 fever days), and subsequently on the third visit (during 
convalescence, 3-4 weeks after the first visit). RT-PCR negative patients were 
used as controls. Results of a preliminary analysis report that of the patients 
enrolled in the study, 133 were confirmed acute dengue cases by RT-PCR. 
There were significant clinical and epidemiological dissimilarities between 
dengue and febrile non-dengue patients, and symptom duration correlated with 
viral load. Preliminary findings underscore the lack of early prognostic indicators 
for dengue fever in adults (Low et al., 2006). The study is on-going. 
 
Identification of patients at high risk for developing severe disease 
remains a great challenge in dengue patient care. Recently, Tanner et al. (2008) 
analyzed clinical, haematological, and virological data to identify diagnostic and 
prognostic algorithms. One diagnostic algorithm can distinguish dengue from 
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other febrile illnesses in the primary care setting with an accuracy of 84.7%. 
Another algorithm can predict severe disease in adults. These findings could be 
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3.1  Patients 
 
Blood samples were collected from January 2008 to November 2008 from 
subjects enrolled in the Early DENgue Infection and Outcomes (EDEN) Study 
(Low et al., 2006). A first blood sample was collected within 72 hours of febrile 
illness (first visit; DK1). Another sample on Day 4-7 of illness was taken on the 
second visit (DK2). Lastly, a third sample was collected on the third visit, 3-4 
weeks after fever onset (DK3). Blood was collected in EDTA-coated tubes 
(Beckton Dickinson, Franklin Lanes, NJ) and stored at the the polyclinic at 4C 
for a maximum of 24 h until analysis. Detection of DENV RNA by RT-PCR to 
diagnose DENV infection was performed at the DSO National Laboratories. A 
more detailed description of the collection procedure can be read in the paper by 
Low and co-workers (2006). 
 
Control febrile dengue-negative patients included those with other undefined 
infections as we do not have information of the infection of most of our patient 
samples. Normal control subjects were not included in our analyses. 
 
The dengue-positive patient samples analyzed in this thesis are presented in 
Table 3.1.  
79 | P a g e  
 
Table 3.1. Dengue positive patients whose blood samples were analyzed by 
antibody labeling and flow cytometry. 
 
Patient codesa Collected samples 
07K3623 DK1, DK2, DK3 
07K3640 DK1, DK2, DK3 
07K3641* DK1, DK2, DK3 
07K3644* DK1, DK2, DK3 
07K4383* DK1, DK2, DK3 
08K3110 DK1, DK2 
08K3111 DK1, DK2, DK3 
08K3114* DK1, DK2, DK3 
08K3115* DK1, DK2, DK3 
08K3126* DK1, DK2, DK3 
08K3136 DK1, DK2, DK3 
08K3140* DK1, DK2, DK3 
08K3143* DK1, DK2, DK3 
08K6576 DK1, DK2, DK3 
08K6579* DK1, DK2, DK3 
08K6580* DK1, DK2, DK3 
08K6583* DK1, DK2, DK3 
08K6586 DK1, DK2, DK3 
08K6587 DK1, DK2, DK3 
08K6599 DK1, DK2, DK3 
 
a Dengue infection was defined by a positive quantitative real time RT-PCR test 
of DENV gene. 
Patient indicated in red had severe dengue as defined by a platelet count of 
<5X104/ul. 
* Patients with secondary dengue infection identified by a positive anti-DENV IgG 
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For febrile non-dengue controls, 60 samples were included in the analyses. In 
some cases, particularly from the non-dengue control group, some patients did 
not complete all three visits. In certain instances, some samples were excluded 
in the analyses when erythrocytes in whole blood were not thoroughly lysed 
during the antibody-labeling steps. 
 
3.2  Antibody-labeling of whole blood and FACS analysis 
 
70 ml of blood was transferred to FACS tubes. After the addition of 50 μl of 
antibody cocktail (Table 3.2), the mixtures were incubated for 15 min at room 
temperature. 1 ml of erythrocyte lysis buffer (BD FACS lysing solution) was then 
added and incubated for 15 min at room temperature. For washing, 2 ml FACS 
buffer (2% FCS, 10 mM EDTA, 0.1% NaN3, in PBS) was added before 
centrifugation 400 g for 4 min in Sorvall Legend. The supernatant was removed 
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Table 3.2. Antibody cocktails used to label whole blood cells. 





































Samples were analyzed on a Beckton-Dickinson FACS Calibur flow 
cytometer (San Jose, CA) within 3 hrs of staining. Data were analyzed using 
FlowJo software (Tree Star Inc., San Carlos, CA). Lymphocyte populations were 
identified/gated using forward and sideward scatter characteristics.  
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3.3 Statistical Analysis  
 
 Student‟s t test was performed on all data using GraphPad Prism version 
4.00 for Windows, GraphPad Software (San Diego California USA, 
www.graphpad.com), whereby p<0.05 was considered significant. 
 
3.4  Isolation of Peripheral Blood Mononuclear Cells (PBMCs)  
 
Blood samples were transferred to CPT tubes (Becton-Dickinson, Franklin 
Lanes, NJ) and were spun for 15 min at 1700 g at room temperature in Sorvall 
Legend centrifuge. The cells and plasma were washed with 4 volumes PBS pH 
7.2 and centrifuged for 4 min at 400 g. The supernatant was discarded and the 
pellet was resuspended in PBS pH 7.2. (A 10ul aliquot was taken for cell 
counting in a Neubauer haemocytometer.) The tube was centrifuged for 4 min at 
400 g. The supernatant was discarded and the cell pellet resuspended in 500 ul 
freezing medium (RPMI 1640, Carlsbad, CA containing 20% FBS, 10% DMSO) 
and transferred to a cryotube. Cryovials containing the cell suspension were 
placed in isopropanol containers (Mr. Frosty, Nalgene, Rochester, NY) at -80C 
overnight and then stored in liquid nitrogen until use. 
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3.5  Plasma  Isolation 
 
After removal of blood for PBMC isolation and surface marker analysis, the 
remaining blood in EDTA-coated Pax tubes was centrifuged in a Sorvall Legend 
for 15 min at 1200 xg at room temperature. Plasma was transferred to a screw-
capped Eppendorf tube and stored in -80C until further use.  
 
3.6  IFN-γ T cell enzyme-linked immunospot (ELISPOT) 
 
3.6.1 Peptide synthesis 
 
Peptides were synthesized by GenScript Corp., Scotch Plains, NJ. Peptide 
sequences are presented in Table 3.3. Peptides were diluted to 4 mg/ml in PBS, 
10% DMSO. Of these peptides, only 19 (peptides 1, 2, 3, 4, 6, 7, 10, 11, 12, 14, 
15, 16, 17, 18, 19, 20, 21, 22, 23) were used in the experiments because the 
remaining peptides were insoluble in DMSO. The peptides were derived from the 
majority consensus sequence of the DENV 2 NS3 protein from all reported 
DENV 2 sequences available online as per year 2008 (courtesy of Dr. Ong Swee 
Hoe). 
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Table 3.3. Amino acid sequences of Pan-DENV overlapping peptides 
(overlapping by 8 amino acids) spanning the immunodominant NS3 protein of 
DENV serotype 2 majority consensus sequence. 
Peptide Number Amino Acid Sequence 
1 GTSGSPIVDRKGKVV (133-147) 
2 VDRKGKVVGLYGNGV (140-154) 
3 VGLYGNGVVTRSGAY (147-161) 
4 VVTRSGAYVSAI (154-165) 
5 GREIVDLMCHATFTM (247-261) 
6 MCHATFTMRLLSPVR (261-275) 
7 MRLLSPVRVPNYNLI (268-282) 
8 RVPNYNLIIMDEAHF (275-289) 
9 IIMDEAHFTDPAS (282-294) 
10 ISEMGANFKAERVID (411-425) 
11 FKAERVIDPRRCMKP (418-432) 
12 DPRRCMKPVILTDGE (425-439) 
13 PVILTDGEERVILAG (1906-1920) 
14 EERVILAGPMPVTHS (1913-1927) 
15 GPMPVTHSSAAQRRG (1920-1934) 
16 SSAAQRRGRIGRNP (1927-1940) 
17 KMLLDNINTPEGIIP (493-507) 
18 NTPEGIIPSMFEPER (500-514) 
19 PSMFEPEREKVDAID (507-521) 
20 REKVDAIDGEYRLRG (514-528) 
21 DGEYRLRGEARKTFV (521-535) 
22 GEARKTFVDLMRRGD (528-542) 
23 VDLMRRGDLPVWLAY (535-549) 
 




100 μl of a solution of anti-IFN-  monoclonal antibody (1-DIK; Mabtech; 
1:2000 dilution, 5 μg/ml in PBS, pH 7.2) was placed into each well of a 
MSHAN4510 plate (Millipore, Billerica, MA) and incubated at 4C overnight. The 
contents of the plate were flicked out to remove excess antibody and the plate 
was washed with sterile PBS four times. 100 μl of blocking solution (RPMI 1640, 
10% FBS) was added and incubated for 30 min at room temperature and washed 
once with PBS before addition of the following: 35 μl RPMI (10% FBS), 15 μl of 
DENV peptides (1:5 dilution of 4 mg/ml stock peptides in RPMI, 10% FBS), and 
100 μl of PBMCs (105 – 3x105 cells) in RPMI, 10% FBS. The positive control 
wells contained 15 μl of phytohemagglutinin (PHA; final concentration 0.5 μg/ml) 
in RPMI (10% FBS) instead of peptide solution. The negative control wells 
contained 15 μl of RPMI (10% FBS) without peptide or PHA or wells to which no 
PBMC was added. The plate was then incubated at 370C overnight. The cells 
were discarded and wells were washed four times with PBS, after which 100 μl of  
biotinylated anti-human IFN-  mAb (Mabtech) (1:2000 dilution) was added. The 
plate was washed with PBS four times after incubation at room temperature for 2 
hr, followed by the addition of 100 μl/well of streptavidin-conjugated peroxidase 
(Sigma, cat. No. S2438; 1:2000 dilution), and incubation at room temperature for 
1 hr. After washing with PBS, 100 μl/well of a solution of the chromogenic 
substrate amino-ethyl carbazol (AEC, 0.3 mg/ml in 0.1 M sodium acetate buffer 
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pH 5.0) and hydrogen peroxide (4 μl of 30% solution added per 10 ml AEC 
solution) was added and incubated in the dark at room temperature for 5-15 
minutes. Finally, coloring process was stopped by washing the plate with tap 
water and the plate was dried at room temperature. The spots were counted 
using an AID-ELISpot Reader (Autoimmun Diagnostika, GmbH, Strassberg, 
Germany). Responses were considered positive when the number of spot-
forming units (SFUs) per 105 PBMCs was twice the number of SFUs in the 
negative control wells and greater than 15 SFU/well. 
 
3.7 Stimulation of PBMCs with DENV peptide pools, surface 
staining for T cell markers, and intracellular staining for 
interferon-γ 
 
3.7.1 PBMC stimulation 
 
Cryopreserved PBMCs were thawed at 370C, and washed twice with RPMI 
(10% FBS), spinning at 500xg in Sorvall Legend centrifuge after each wash. 
Cells were distributed to a round-bottomed 96-well plate at 105 cells per well. 
Cells were cultured with synthetic peptide pools (Table 3.3) at a final 
concentration of 250 μg/ml for each peptide in a total volume of 200 μl of RPMI 
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1640 (10% FBS). As a positive control 12-O-tetradecanoyl-phorbol-13-acetate (or 
phorbol myristate acetate, PMA, 0.5 μg/ml final concentration) and ionomycin 
(4.5 μg/ml final concentration) were added. As a negative control, only medium 
(RPMI 1640, 10% FBS) was added. Brefeldin A (5 μg/ml final concentration) and 
IL-2 (final concentration 0.02 μg/ml) were added to all wells before incubation at 
370C for 5 hours.  
 
3.7.2 Staining for cell surface antigens and intracellular IFN-γ 
 
 The cells were washed with FACS buffer, centrifuged for 3 min at 400 xg in 
Sorvall Legend, and the supernatant was discarded. The cells were incubated 
with 50 μl antibody cocktail (anti-CD3-PE, 1:20; anti-CD4- Alexa Fluor 647, 
1:200; anti-CD8-PerCP, 1:40) against surface antigens for 15 min at 4C, after 
which cells were washed with FACS buffer. Cells were permeabilized using the 
Cytofix/Cytoperm Plus kit (Pharmingen) for 15 min at room temperature, and 
then washed with FACS permeabilization buffer (FACS-Perm; 2% FCS, 10 mM 
EDTA, 0.1% NaN3, 0.1% saponin in 1 L PBS). Intracellular
 staining was 
performed using 50 μl FITC-conjugated anti-IFN-γ (1:40 in FACS-Perm) for 30 
min at 4C. The cells were then washed twice with FACS-Perm, spinning at 400 
xg for 3 min after each wash. Finally, the cells were resuspended in 200 μl FACS 
buffer and analyzed by flow cytometry.     
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Table 3.4. Peptide pools used to stimulate PBMCs. 
Peptide Pools Peptide Content 
1 Peptides 1, 2, 3 ,4 
2 Peptides 6, 7, 10, 11 
3 Peptides 12, 14, 15, 16 
4 Peptides 17, 18, 19, 20 
5 Peptides 21, 22, 23 
 
 
3.8 DENV-specific T-cell line establishment 
 
PBMC (5X105) from different dengue-seropositive healthy individuals were 
cultured with peptide pools (250 μg/ml of each peptide) in 0.2 ml RPMI 1640 
containing 10% fetal calf serum in 96-well round-bottomed plate. On day 3, IL-2 
was added at a final concentration of 0.02 µg/ml. On day 8, PBMCs were re-
stimulated with peptide pools for 5 h and assayed for intracellular IFN-γ 
production by flow cytometry. PBMC culture from one donor which produced IFN-
γ was chosen for further culture. On day 12, cells from the chosen donor were 
cultured at a concentration of 50 cells/well with 105 γ-irradiated (3000 rad) 
autologous PBMC (pulsed with peptide pools at 250 μg/ml of each peptide) in 0.2 
ml RPMI 1640 containing 10% FCS and 0.02 µg/ml in 96-well round-bottomed 
plate. Half of the medium was replaced every time it turned yellow, maintaining 
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the same final concentrations of peptide pools and IL-2 as above. On day 32, γ-
irradiated (2000 rad) autologous PBMC (pulsed with peptide pools at 250 μg/ml 
of each peptide) were added to the cultures in 0.2 ml RPMI 1640 containing 10% 
FCS and 0.02 µg/ml. The cultures were maintained until day 84. Assays for 
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4.1 Activation and phenotypic changes in natural killer cells, 
CD56-expressing T cells, and T cells in patient PBMCs during 
acute dengue infection and convalescence 
 
 
4.1.1 Natural killer cells 
 
We sought to investigate the role that NK cells might play after infection 
with dengue virus by assessing the frequency and distribution of NK cells in the 
circulating blood of dengue and febrile non-dengue patients.  
 
Figure 4.1 shows how NK cells were defined by immunophenotyping and 




92 | P a g e  
 
  A 














































        
Figure 4.1. Gating strategy to define NK cells (CD56+CD3-). Leukocytes defined 
by forward scatter (FSC) and side scatter (SSC) (A) were gated on CD3- 
population, then setting the CD56 gate on this population (B). At least 20 
000 leukocyte gated events were acquired. Since we started to count cells 
manually with a Neubauer counting chamber we gated on leukocytes to 
be able to calculate absolute numbers. However we got access to the 
lymphocyte numbers counted by hemocytomer later on and thus switched 
to gating on lymphocytes for the T cell analysis 
 
 
The frequency of CD56+CD3- cells (NK cells) was not significantly 
different between dengue patients and febrile non-dengue patients at all time 
points (Figure 4.2). The frequency of NK cells increased significantly during 
defervescence (4-7 days after disease onset) in both patient groups, where this 
increase in NK cell frequency was more significant in the febrile non-dengue 
patients than in dengue patients. The increase in NK cell frequency in dengue 
patients and control febrile patients may reflect the diseased states in these 
patients and underscores the importance of NK cells during infection. There was 
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a significant decrease in the frequency of NK cells at convalescence (after 3-4 
weeks) in dengue- but not in febrile non-dengue controls (Figure 4.2). Azeredo et 
al. (2005) observed higher frequencies of NK cells in dengue patients than in 
healthy controls especially during the early acute phase of infection (1-5 days 
after disease onset) and also during the late acute phase (6-10 days after 
disease onset) and convalescence (after 11 days).  
 































































Figure 4.2. Percentage of NK cells (CD56+CD3-) in febrile non-dengue and 
dengue patients at different time points after onset of fever. Whole blood 
from febrile non-dengue subjects in the acute (DK1; n=53), defervescent 
(DK2; n=28), and convalescent (DK3; n=36) phases and from dengue 
patients (DK1, n=15; DK2, n=14; DK3, n=14) were labeled as described in 
the Materials and Methods analyzed by flow cytometry within the 
leukocyte gate. Statistical significance was assessed by Student‟s t test 
***p<0.0001. 
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 Absolute numbers of leukocytes were significantly lower in dengue 
patients compared to febrile non-dengue individuals during the acute and 
defervescent phases. Although the frequencies of NK cells amongst leukocytes 
in both dengue and febrile non-dengue groups were similar, dengue patients 
have significantly lower number of NK cells during defervescence compared to 
febrile non-dengue individuals (Figure 4.3).   
 
In the present study, the expression of the early activation marker CD69 
by CD56+CD3- cells (Figure 4.4) was analyzed, where striking differences 
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Figure 4.3. Absolute number of leukocytes (A) and NK cells (B; CD56+CD3-) in 
febrile non-dengue and dengue patients at different time points after onset 
of fever. Absolute cell numbers were obtained by haemocytometer counts 
of  blood of febrile non-dengue acute (DK1; n=53), defervescent (DK2; 
n=28), and convalescent (DK3; n=36) phases and of dengue patients 
(DK1, n=15; DK2, n=14; DK3, n=14). Statistical significance was assessed 
by Student‟s t test ***p<0.0001. 
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Figure 4.4.  Representative dot plot for the expression of CD69 on CD56+CD3- 
NK cells. Using the gating strategy described in Figure 4.1, CD69 gate 
was set on CD56+CD3- population.  DK3 of the same patient was used as 
a reference to set the gate for CD69 expression if the population was not 




Despite the similarity in absolute NK cell number during the acute phase  
in dengue and febrile non-dengue groups and the significantly lower number of 
NK cells during the defervescent phase in dengue patients compared to non-
dengue controls (Figure 4.3), the frequency of CD69+ cells among NK cells 
(CD56+CD3-) was significantly higher in dengue patients compared to non-
dengue patients at the acute and defervescent phases of infection (Figure 4.5a). 
The increase in frequency of activated NK cells in dengue patients peaked at the 
acute phase and decreased at defervescence, with a significant decrease at 
convalescence. The frequency of NK cells that express CD69 at convalescence 
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was similar in dengue and non-dengue patients (Figure 4.5a). These 
observations indicate that activated NK cells were among the mononuclear 
leukocytes that are efficiently activated after dengue infection, despite their lower 
absolute numbers (Figure 4.3). These results were consistent with those 
observed by Azeredo and co-workers (Azeredo et al., 2005) and Green and co-
workers (Green et al., 1999).  
 
However, the absolute numbers of CD69-expressing NK cells did not differ 
significantly between dengue and febrile non-dengue controls (Figure 4.5b). This 
indicates that a similar number of, NK cells is activated in dengue patients as in 
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Figure 4.5. Percentage (A) and absolute numbers (B) of NK cells expressing the 
activation marker CD69 in dengue and non-dengue patients after the 
onset of fever. Whole blood from febrile non-dengue subjects in the acute 
(DK1; n=53), defervescent (DK2; n=28), and convalescent (DK3; n=36) 
phases and from dengue patients (DK1, n=15; DK2, n=14; DK3, n=14) 
were labeled as described in the Materials and Methods analyzed by flow 
cytometry within the leukocyte gate. Absolute cell numbers were obtained 
by haemocytometer counts of blood of the same donors as above. 
Statistical significance was assessed by Student‟s t test ***p<0.0001 
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We did not observe significant difference in the percentage and absolute 
counts  of activated NK cells between patients with primary and secondary DENV 
infection (data not shown). This suggests that DENV infection can efficiently 
stimulate innate immune responses independent of previous infection. 
 
4.1.2 CD3+ lymphocytes expressing CD56 
 
 
The understanding of the role of CD56-expressing T lymphocytes cells in 
viral infections is limited. Hence, to investigate the role they play in dengue, the 
frequency and distribution of CD56-expressing T lymphocytes in whole blood 
samples of dengue and non-dengue patients were compared.  
 
In both dengue and non-dengue febrile patients, there was a significant 
drop in the percentage of total lymphocytes amongst white blood cells during the 
fever phase of infection (Figure 4.6). The absolute number of lymphocytes was 
also down during the acute phase of infection in both patient groups, but was 
significantly lower in dengue patients than in febrile non-dengue controls until 
defervescence (Figure 4.7). 
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Figure 4.6. Percentage of total lymphocytes in dengue and non-dengue patients 
after the onset of fever. Whole blood from febrile non-dengue subjects in 
the acute (DK1; n=74), defervescent (DK2; n=46), and convalescent (DK3; 
n=39) phases and from dengue patients (DK1, n=19; DK2, n=18; DK3, 
n=11) were labeled as described in the Materials and Methods analyzed 
by flow cytometry within the lymphocyte gate. Statistical significance was 
assessed by Student‟s t test ***p<0.0001. 
 
Lymphocytes generally comprise 20-40% of circulating leukocytes. 
Lymphocyte frequencies returned to normal levels during defervescence and 
convalescence (Figure 4.6). The absolute lymphocyte counts in both dengue and 
febrile non-dengue patients were similar during convalescence (Figure 4.7). Our 
observations were consistent with those of previous reports which showed that 
the absolute count for lymphocytes is decreased in dengue patients compared to 
healthy controls, with severe dengue cases having lower number of lymphocytes 
than those with mild dengue (Green et al., 1999). The decrease in the frequency 
of lymphocytes during the acute phase both in dengue and febrile non-dengue 
controls may reflect the inflammation in both patient groups. The significantly 
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lower absolute lymphocyte count in dengue patients compared to that in febrile 
non-dengue controls suggests the existence of more highly inflammatory 















































Figure 4.7. Absolute number of lymphocytes in febrile non-dengue and dengue 
patients at different time points after onset of fever. Absolute cell numbers 
were obtained by haemocytometer counts of blood of febrile non-dengue 
acute (DK1; n=74), defervescent (DK2; n=46), and convalescent (DK3; 
n=39) phases and of dengue patients (DK1, n=19; DK2, n=18; DK3, n=11). 
Statistical significance was assessed by Student‟s t test ***p<0.0001. 
 
 
The increase in the proportion of lymphocytes at DK2 can be attributed to 
the decrease in the absolute number of leukocytes (Figure 4.3A), particularly that 
of the neutrophils (results from EDEN study, not shown). Leukopenia, the 
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decrease in the number of circulating leukocytes in the blood, generally 
characterizes dengue, where the absolute numbers of lymphocytes, monocytes, 
and neutrophils decline (Kalayanarooj et al., 1997).  
 
CD56-expressing T lymphocytes were defined as CD56+CD3+ cells flow 
cytometry analysis (Figure 4.8).  
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Figure 4.8. . Gating strategy to define CD56+CD3+ cells. Lymphocytes defined 
by forward scatter (FSC) and side scatter (SSC) (A) were gated on the 
CD3+CD56+ population (B). At least 20 000 lymphocyte gated events 
were acquired. 
 
The frequency of CD56+CD3+ cells did not significantly differ between 
dengue patients and febrile non-dengue patients at all time points analyzed 
(Figure 4.9), contrasting  the observation by Azeredo and co-workers (2005) that 
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the frequency of CD56+ T cells increased during the acute phase of infection in 
dengue patients.  However, the highly significantly lower numbers of lymphocytes 
in dengue patients compared to febrile non-dengue controls during the acute and 
defervescent phases of infection caused significantly lower number of CD56+ 
CD3+ lymphocytes during the acute and defervescent phases in dengue patients 
(Figure 4.10).  
 
 































































Figure 4.9.  Percentage of CD56+CD3+ cells in non-dengue and dengue patients 
after the onset of fever. Whole blood from febrile non-dengue subjects in 
the acute (DK1; n=53), defervescent (DK2; n=27), and convalescent (DK3; 
n=35) phases and from dengue patients (DK1, n=15; DK2, n=14; DK3, 
n=14) were labeled as described in the Materials and Methods analyzed 
by flow cytometry within the lymphocyte gate. Statistical significance was 
assessed by Student‟s t test ***p<0.0001. 
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Figure 4.10. Absolute number of CD56+ CD3+ cells in febrile non-dengue and 
dengue patients at different time points after onset of fever. Absolute cell 
numbers were obtained by haemocytometer counts of  blood of febrile 
non-dengue acute (DK1; n=53), defervescent (DK2; n=28), and 
convalescent (DK3; n=36) phases and of dengue patients (DK1, n=15; 
DK2, n=14; DK3, n=14). Statistical significance was assessed by 
Student‟s t test ***p<0.0001. 
 
 
As was observed with NK cells, the frequency of cells that express CD69 
among CD56+CD3+ cells (Figure 4.11) in dengue patients compared to non-
dengue patients at the acute and defervescent phases of disease differed highly 
significantly (Figure 4.12a), notwithstanding the significantly decreased absolute 
number of lymphocytes in dengue patients The frequency of activated 
CD56+CD3+  cells in dengue patients peaked during the acute phase (DK1) and 
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declined at defervescence (DK2), and was significantly higher compared to that 
in non-dengue patients at both time points. There was a significant decrease in 
the percentage of activated cells at convalescence, with comparable frequency of 
CD69-expressing CD56+CD3+ cells in dengue and non-dengue patients, in spite 
of the number of lymphocytes beginning to increase. 
 

































Figure 4.11. Representative dot plot for the expression of CD69 on CD56+CD3+ 
cells. Using the gating strategy described in Figure 4.5, CD69 gate was 
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We observed no difference in the absolute numbers of CD69-expressing 
CD56+CD3+ cells between dengue and febrile non-dengue controls during the 
acute phase of infection. However, the absolute number of these cells was 
significantly higher in dengue patients compared to febrile non-dengue patients 
during defervescence (Figure 4.12b). This indicates that in terms of absolute cell 
count, CD56+CD3+ cells are more activated in dengue patients compared to 
febrile non-dengue patients during the defervescent phase of infection. The 
absolute cell count of activated cells may be more of more significance than the 
percentage of activated cells. 
 
The percentage and absolute numbers of activated CD56+CD3+  cells did 
not differ significantly between dengue patients with primary and secondary 
infection (data not shown),  
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Figure 4.12. Percentage (A) and absolute numbers (B) of CD56+CD3+ cells 
expressing the activation marker in dengue and non-dengue patients after 
the onset of fever. Whole blood from febrile non-dengue subjects in the 
acute (DK1; n=53), defervescent (DK2; n=27), and convalescent (DK3; 
n=35) phases and from dengue patients (DK1, n=15; DK2, n=14; DK3, 
n=14) were labeled as described in the Materials and Methods and 
analyzed by flow cytometry within the lymphocyte gate. Absolute cell 
numbers were obtained by haemocytometer counts of blood of the same 
donors as above. Statistical significance was assessed by Student‟s t test 
***p<0.0001. 
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4.1.3 T Lymphocytes 
 
To date, human anti-DENV T cell responses have not been extensively 
explored and correlates of protective anti-DENV T cell immunity are poorly 
documented. The current knowledge derives from mouse studies, from in vitro 
re-stimulated cells from patients and from patient-derived T cell lines. Since 
dengue disease outcome may be determined, in part, by the immune system and 
since the T cell response may determine disease severity, T cell immune status 
after dengue infection was investigated in this project. We analyzed CD4+ and 
CD8+ T cell activation longitudinally during the course of dengue infection up to 
convalescence. One aim was to clarify the role of T cells in protective immunity 
versus immunopathology.  
 
Figure 4.13 shows how lymphocytes were identified based on the forward 
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Figure 4.13. Gating strategy to define T lymphocyte subpopulations. (A) 
Lymphocytes were gated based on forward scatter (FSC) and side scatter 
(SSC) and gated into CD3+ population (B), then setting the CD4 (C) and 
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In dengue patients, there is a significantly lower percentage of CD3+ 
lymphocytes than in non-dengue febrile patients during the acute phase of 
infection (Figure 4.14).  While the levels of CD3+ lymphocytes significantly 
increased in both dengue and febrile non-dengue patients 4 days after fever 
onset, the rise of CD3+ lymphocytes in febrile non-dengue patients was more 
significant than in dengue patients.  The levels of CD3+ lymphocytes were 
maintained from 4 days post fever onset up to convalescence in febrile non-
dengue controls, but decreased in dengue patients. Although this decrease in 
the % of T cells in dengue patients was not statistically significant, this resulted in 
a significantly different % of T cell between the two patient groups at 
convalescence. The term convalescent may thus be questioned for the one 
month collection time point when addressing T cell responses. 
 
Sarasombath et al. (1988) reported decreased CD3+ cells in the febrile 
stage of young (8 months to 12 years old) DHF patients and observed lowest 
CD3+ cell counts on the first day of fever subsidence or shock. In the present 
study which involved adult patients and did not include severe dengue cases, the 
percentage of CD3+ T cells amongst lymphocytes increased during 
defervescence in dengue patients.  
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Figure 4.14. Percentage of CD3+ T cells amongst total lymphocytes in dengue 
and non-dengue patients after the onset of fever. Whole blood from febrile 
non-dengue subjects in the acute (DK1; n=75), defervescent (DK2; n=39), 
and convalescent (DK3; n=35) phases and from dengue patients (DK1, 
n=20; DK2, n=17; DK3, n=17) were labeled as described in the Materials 
and Methods analyzed by flow cytometry within the lymphocyte gate. 
Statistical significance was assessed by Student‟s t test ***p<0.0001. 
 
 
Wells et al. (1980) reported significantly reduced absolute number of T 
cells during acute DHF. Post-mortem histopathological analysis of DHF patients 
in Myanmar revealed bone marrow hypoplasia and T cell depletion in the thymus 
and thymus-dependent areas of the spleen and lymph nodes (Aung-Khin et al. 
1975).  
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There was no difference in the percentages of CD4+ and CD8+ T cells 
between dengue patients and non-dengue febrile patients at all time points 
(Figure 4.15). However, absolute numbers of leukocytes and lymphocytes were 
~50% lower in dengue compared to non-dengue patients (Figures 4.3 and 4.7), 
which means that numbers of CD4 and CD8 cells are likewise decrease in 
dengue patients. Liu et al. (2002) reported that compared to a normal control 
(DHF patient sampled 9 months post-infection), the proportion of CD8+ cells was 
higher, while that of CD4+ cells was lower. and that this inversion of CD4/CD8 
ratio occurred more frequently in patients with severe dengue than in those with 
mild disease (Liu et al., 2002). Boonpucknavig et al. (1979), Wells et al. (1980), 
and Sarasombath et al. (1988) reported significantly lower mean absolute counts 
of CD4+ and CD8+  T cells during acute DHF. These reports were confirmed by 
Green et al. (1999), who also observed considerably decreased mean absolute 
counts of gamma-delta T cells and NK cells in dengue patients, especially in 
DHF patients, than in healthy controls. Green et al. (1999) proposed that DENV 
infection promotes activation of DENV-specific T cells and other cells, which 
migrate to the liver, lymph nodes, and spleen to eliminate DENV-infected cells. 
These activated cells subsequently undergo apoptosis, which may result in the 
mild elevation of liver enzymes (aspartate and alanine aminotransferases) 
generally observed in acute dengue disease (Kalayanarooj et al., 1997). 
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Figure 4.15. Percentage of CD3+CD4+ (A) and CD3+CD8+ (B) lymphocytes in 
dengue and non-dengue patients after the onset of fever. Whole blood 
from febrile non-dengue subjects in the acute (DK1; n=74), defervescent 
(DK2; n=46), and convalescent (DK3; n=39) phases and from dengue 
patients (DK1, n=19; DK2, n=18; DK3, n=11) were labeled as described in 
the Materials and Methods analyzed by flow cytometry within the 
lymphocyte gate. Statistical significance was assessed by Student‟s t test 
***p<0.0001. 
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4.1.3.1 Phenotyping of DENV-induced effector T cells 
 
Activated CD8+ T cells induce death of virus-infected cells that present 
MHC class I-restricted virus epitopes. A subset of antigen-specific T cells can 
differentiate into memory T cells that persist long after an infection has resolved 
and can rapidly expand to large numbers of effector cells upon re-exposure to 
the associated antigen. In this thesis, the expression patterns of a set of cell 
surface markers on CD3+ lymphocytes after dengue infection was analyzed.  
 
 CD38 and HLA-DR are activation markers that are upregulated on effector 
cells during immune responses (Radziewicz et al., 2007). CD38 is expressed by 
activated T cells during the acute phase of viral infections in humans (Miller et al., 
2008). Activation markers are generally not expressed on quiescent memory 
cells, thus, their expression on effector cells can differentiate these cell subsets 
(Radziewicz et al., 2007). Activation markers are re-expressed by memory cells 
upon re-encounter with antigen (Oxenius et al., 2001). The expression patterns 
of CD38 on CD3+ PBMCs at three time points after DENV infection was 
investigated in order to assess the magnitude and kinetics of T cell responses 
after DENV infection.  
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Figure 4.16 shows how activated (CD38+) naïve (CD45RA+) and effector 
memory (CD45RA-) CD4+ and CD4- T lymphocytes were defined by 
immunophenotyping and flow cytometry analysis.  
 
 In general, it was observed that dengue patients have significantly 
higher % of activated (CD38+) CD3+ T cells than febrile non-dengue controls 
(Figure 4.17). A highly significant difference in % activated T cells between 
dengue patients and non-dengue controls during the acute and defervescence 
phases of infection were observed for CD45RA- (memory) CD3+CD4- (presumed 
cytotoxic T cells) and CD45RA+ (naïve/effector memory) CD3+CD4- (presumed 
cytotoxic T cells) (Figure 4.17A and 4.17B), with the frequency of the memory T 
cell subset still significantly higher compared to that in febrile non-dengue 
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Figure 4.16. (A) Lymphocytes were gated based on forward scatter (FSC) and 
side scatter (SSC) and sub-gated for CD3+ cells (B). CD4+ and CD4- 
gates were set on the CD3+ population (C). Expression of CD38 and 
CD45RA was analyzed in CD3+CD4+ T lymphocytes (D) and CD3+CD4- 
T lymphocytes (E).  
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Figure 4.17. Expression of the activation marker CD38 on  A) CD45RA-(memory) 
CD3+CD4- T cells; B) CD45RA+(naïve/effector memory) CD3+CD4- T 
cells; C) CD45RA-(memory) CD3+CD4+ T cells; D) CD45RA+ 
(naïve/effector memory) CD3+ CD4+ T cells in the peripheral blood of  
dengue and febrile non-dengue patients. Whole blood from febrile non-
dengue subjects in the acute (DK1; n=81), defervescent (DK2; n=48), and 
convalescent (DK3; n=43) phases and from dengue patients (DK1, n=20; 
DK2, n=19; DK3, n=16) were labeled as described in the Materials and 
Methods analyzed by flow cytometry within the lymphocyte gate. 
Statistical significance was assessed by Student‟s t test ***p<0.0001. 
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    The frequency of activated naïve/effector CD4- memory T cell subset in 
dengue patients peaked during the acute phase of infection before gradually 
declining at defervescence and convalescence (Figure 4.17B). The frequency of 
activated CD4+ and CD4- memory T cell subset in both patient groups peaked at 
defervescence and decreased significantly at convalescence (Figure 4.17A and 
4.17C). CD38+ naïve (CD45RA+) helper T cells have relatively lower frequencies 
(1.5%1.1 to 2.4%4.0 of CD4+ cells) compared to the above-mentioned T cell 
subsets and are not significantly different in both patient groups (Figure 4.17D). 
 
 The frequency of CD38-expressing effector memory (CD45RA-) helper T 
cells (CD3+CD4+) differed significantly between the two patient groups during 
defervescence (Figure 4.17C). In both patient groups, there was an expansion of 
the memory helper T cell subset at defervescence, but this expansion was 
significantly higher in dengue patients.  
 
 Activated T cells express CD38 during the acute phase of viral infections 
(Miller et al., 2008). Hence, CD38 expression could be used to evaluate the 
magnitude and kinetics of T cell responses after infection. The increase in the 
frequencies of CD38+ T cells that we observed are most likely DENV-specific T 
cells that have been induced by DENV infection. The frequencies of the activated 
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T cell subsets decreased during convalescence, indicating that these antigen-
specific cells had contracted after pathogen clearance. 
 
 No significant difference in the percentage of activated T lymphocytes 
between patients with primary and secondary DENV infection was observed 
(data not shown), suggesting that DENV infection can stimulate naïve effector 
cells as efficiently as memory cells. Furthermore, this implies that T cell activation 
may determine disease outcome; severe disease can develop in primary or 
secondary infection independent of pre-existing immunity.. 
 
 
4.1.3.2 Changes in T cell subset phenotypes and differentiation stages after 
dengue infection 
 
Lymphocytes were gated based on forward scatter (FSC) and side scatter 
(SSC) and gated into the CD3+ population as previously described in Figure 4.13. 
CD8+ and CD8- gates were set on the CD3+ population (Figure 4.18A, middle 
panel). Expression of CCR7 and CD127 was analyzed on CD3+CD8+ T 
lymphocytes and CD3+CD8- T lymphocytes (Figure 4.18B). 
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Significant differences between dengue patients and febrile non-dengue 
controls were observed for CCR7+CD127+ (central memory) CD8+ CD3+ 
(cytotoxic) T cells and CCR7-CD127- (effector memory) CD8- CD3+ 
(presumptive T helper) cells (Figure 4.16; highlighted in red). During the acute 
phase of infection, the frequency of central memory cytotoxic T cells was 
significantly lower in dengue patients compared to febrile non-dengue controls 
(Figure 4.19A, highlighted in red). This may be due to the recruitment of large 
numbers of these T cells for the anti-dengue response. At defervescence, the 
percentage of these cells increased in both patient groups but was significant 
only in dengue patients.  
 
 


































































Figure 4.18. CD8+ and CD8- gates on the CD3+ lymphocyte population (A), for 
which the expression of CCR7 and CD127 was analyzed (B).       
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Figure 4.19. Expression of CCR7 and CD127 on CD3+CD8+ and CD3+CD8- T lymphocytes in the peripheral blood of dengue and 
febrile non-dengue patients. Left panel are representative diagrams showing the quadrant separating four populations 
of CD3+CD8+ or CD3+CD8- T cells based on CCR7 and CD127 expression. Middle panel shows the percentage of 
CD3+CD8+ T cells (cytotoxic T cells). Right panel shows the percentage of CD3+CD8- T cells (presumptive helper T 
cells)  A) Central memory (CCR7+CD127+) T cells; B) CCR7- CD127+ (Memory); C) CCR7-CD127- (Effector); D) 
CCR7+CD127- (Effector). Highlighted in red are frequencies of T cell subpopulations that significantly differed between 
dengue patients and febrile non-dengue controls. Whole blood from febrile non-dengue subjects in the acute (DK1; 
n=75), defervescent (DK2; n=39), and convalescent (DK3; n=36) phases and from dengue patients (DK1, n=20; DK2, 
n=17; DK3, n=17) were labeled as described in the Materials and Methods analyzed by flow cytometry within the 
lymphocyte gate. Statistical significance was assessed by Student ‟s t test ***p<0.0001. 
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On the other hand, the frequency of effector memory (presumptive T 
helper) cells was significantly higher in dengue patients compared to control 
patient group during the acute phase of infection (Figure 4.19C, highlighted in 
red). These cells increased in frequency during the acute phase in dengue 
patients but not in febrile non-dengue controls, where it remained constant at all 
time points (Figure 4.19C).  
 
The percentages of central memory CD8+ T cells and effector memory 
CD8- (presumptive T helper) cells did not differ between dengue patients with 
primary and secondary infection (data not shown). In primary infection, the 
CCR7-CD127- phenotype may represent newly activated DENV-specific cells or 
non-DENV-specific effector memory cells.  
 
Taken together, this profile shows massive changes in the T cell 
compartments of dengue patients potentially leading to the establishment of high 
numbers of memory cells. Reactivation of these during secondary infection might 
cause immunopathology due to the high amounts of cytokines produced. It is 
also remarkable that CCR7- effector cells were increased in dengue, suggesting 
accumulation of activated cells in the periphery. 
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Based on these results, the correlation of cell surface phenotypes of the T 
cell subsets with their functional characteristics should be further investigated in 
functional assays. Knowledge of the functions of DENV-induced T cells could aid 
in understanding how they contribute to dengue protective or pathologic immunity. 
 
 
4.2  IFN-γ T cell enzyme-linked immunospot (ELISPOT) 
responses to peptides spanning the DENV2 NS3 antigen  
 
 
4.2.1 IFN-γ  responses from patients and dengue-immune healthy individuals 
 
IFN-γ ELISPOT assays were performed to investigate the extent and 
magnitude of T cell responses of PBMCs from dengue patients and healthy 
dengue-immune individuals to a panel of 19 overlapping peptides (15-mers 
overlapping by 8 amino acids) derived from the NS3 protein of DENV serotype 2 
majority consensus sequence. Responses were considered positive when the 
number of spot-forming units (SFUs) per 105 PBMCs per well was twice the 
number of SFUs in the negative control wells and greater than 10 SFU/well.  
 
Tested patient PBMCs included one acute phase sample (collected 1-3 days 
post-fever onset), 6 defervescent phase samples (collected 4-7 days post-fever 
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onset), and 6 convalescent phase samples (collected 3-4 weeks post-fever 
onset) (Table 4.1). Patient PBMC samples were from 3 febrile non-dengue 
patients who were DENV-seropositive, 2 were from dengue patients with no 
previous dengue infection, and 5 were from dengue patients determined to have 
secondary dengue infection (Table 4.1). Secondary infection is defined as a 
positive IgG ELISA test during the acute phase of infection. In addition to patient 
samples, PBMCs from 4 healthy, DENV-seropositive individuals (Table 4.1) were 
included in the assays.  
 
Overall, 8 (of 14) EDEN patient PBMCs responded to at least one of the 19 
peptides in the IFN-γ ELISPOT assay (Table 4.2). Five samples did not 
recognize any of the peptides. Some defervescent and convalescent phase 
samples responded at least one peptide. One sample collected during 
convalescence (2867DK2) exhibited responses to 15 of the peptides. Out of the 
four healthy DENV-immune samples, two (44505 and 36766) responded to 
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Result of DENV PCR 
 










 + + (secondary infection)
 **
 No data available 
2361
 a*










































 NA + NA 
36766
 b
 NA + NA 
44505
 b
 NA + NA 
68207
 b
 NA + NA 
76907
 b
 NA + NA 
 
a EDEN patient; * indicates febrile non-dengue patient 
b Healthy DENV-seropositive person 
NA – not applicable 
** - PBMC taken during febrile phase 
#   - tested negative in ELISA but gave a positive result during the acute phase in dot 
blot assay 
      Table 4.2. IFN-γ responses of dengue patients and healthy dengue-immune individuals to DENV 2 majority consensus sequence NS3 epitopes. 
 
*with secondary infection
The magnitude of positive responses of PBMCs to 19 individual DENV 
NS3 peptides is summarized in Figure 4.20. The strongest responses based on 
SFU/105 cells were observed for the convalescent sample 2314DK3 but gave 
responses to only three peptides. It could be that DENV-specific T cells 
recognizing these three peptides are present in relatively higher numbers giving 
high numbers of SFU. Sample 2867DK3 which responded to the most number 
(15) of peptides also gave relatively strong responses. Strong responders 
included PBMCs from defervescent and convalescent patients but not those from 
healthy dengue seropositive individuals. DENV-specific T cells recognizing a 
variety of peptide antigens may be present in amounts not sufficient to give high 
numbers of SFUs in weak responders ) 
 
Whereas samples that gave the strongest responses to some peptides 
were one convalescent and a healthy dengue-seropositive sample, we cannot 
generalize that a higher T cell response is characteristic of the convalescent 
phase because of the limited number of samples evaluated. However, a number 
of reports have observed higher T cell responses in convalescent phase 
compared to the acute phase (Zivna et al., 2002; Mongkolsapaya et al., 2003; 
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Figure 4.20.  Levels of T cell responses to individual DENV2 NS3 peptides of 
patient PBMCs collected at different time points after DENV infection. The 
red dashed line indicates the cut-off point, which was taken as the mean 
of SFUs observed in the negative control (no peptides). Responses were 
considered positive if SFU/105 cells were twice the number SFU in 
negative control and greater than 10 SFU/well. (Continued on next page)     
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Figure 4.20 (continued from preceding page). Levels of T cell responses to 
individual DENV2 NS3 peptides of patient PBMCs collected at different 
time points after DENV infection. The red dashed line indicates the cut-off 
point, which was taken as the mean of SFUs observed in the negative 
control (no peptides). Responses were considered positive if SFU/105 





No 5-day incubation 68207
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4.2.2 Correlation of disease severity with T cell response 
 
Only 1 PBMC donor (2837) had severe disease (defined by platelet count 
<5x104/ul) and this patient did not have prior DENV infection. The PBMCs 
collected at defervescence did not recognize any of the 19 peptides we used in 
ELISPOT. As this patient had no encounter with DENV before the present 
infection, the T cell response might not have been established at detectable 
frequency at defervescence, hence the negative response. It would have been 
interesting to check the response of PBMCs from this patient taken during 
convalescence.  
 
PBMC sample collected during convalescence (2867DK3) from a dengue 
patient with no previous DENV infection responded to 15 peptides with relatively 
high numbers of SFU, indicating that the T cell response has sufficiently 
expanded at this time point to be detectable and that the established T cell 
repertoire recognized various peptide antigens. That 2867DK3 PBMCs taken 
during convalescence from a patient with primary dengue infection can elicit 
comparable or even better responses (in terms of the number of peptides 
recognized) than PBMCs taken during the same time point from patients with 
secondary dengue infection (2314DK3). In terms of the number of SFU, however, 
2314DK3 showed better responses than 2867DK3. 
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In general, the specificity of T cell responses was donor-dependent. It 
cannot be conclusively stated that the time of sample collection (acute phase, 
defervescence, or convalescence) can influence T cell responses. There was no 
difference in the extent and magnitude of responses between patients with 
primary infection and those with secondary infection, provided the PBMCs were 
collected at convalescence. The extent and magnitude of responses did not 
correlate (i.e. samples that responded to more peptides did not necessarily have 
high SFUs). These observations may reflect the spectrum of factors that 
influence immunodominance.   
 
Although only 1-3 (out of 17) samples gave responses to each of the 19 
peptides used in this study, all 19 of them evoked responses from at least one 
PBMC sample (Table 4.2), suggesting that they contain antigens recognized by 
the PBMC samples used in this study. In some cases, contiguous and 
overlapping peptides elicited a response in the same PBMC sample (Table 4.2), 
indicating that the peptides have a shared epitope or that overlapping epitopes 
may be present.   
 
All the peptides used in our study were derived from the majority consensus 
sequence of the DENV 2 NS3 protein from all reported DENV 2 sequences 
available online as per year 2008. The DENV NS3 protein is the most 
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predominantly recognized T cell target and contains the largest number of 
antigenic peptides (Mathew et al., 1996; Simmons et al., 2005; Appanna et al., 
2007). NS3 possesses protease (N-terminus) and nucleotide 
triphosphatase/helicase (C-terminus) activities and is highly conserved across all 
DENV serotypes and among flaviviruses (Valle and Falgout, 1998), which may 
account for its high immunogenicity. Several sites on NS3 have been reported to 
be recognized by CD8+ CTLs (Mathew et al., 1996; Simmons et al., 2005; 
Appanna et al., 2007) and CD4+ CTLs (Kurane et al., 1991; Zeng et al., 1996; 
Simmons et al., 2005), but no distinct immunodominant epitope has been 
identified (Mathew et al., 1996). Appanna et al. (2007) reported that position 422-
431 evoked the strongest T cell responses. Position 200-324, which is more 
conserved (78%) than the NS3 as a whole (68%), was identified as the region 
where most antigenic peptides cluster (Simmons et al. 2005).  
 
In PBMC samples taken from individuals with previous DENV infection 
(patients with secondary DENV infection and DENV-seropositive healthy 
persons), the peptides can restimulate DENV-specific T cells generated during 
an earlier DENV infection.  We could not determine the cross-reactivity of these 
DENV-specific cells because of the lack of information on the primary infecting 
serotype and the secondary infecting serotype. This is important as dengue 
immunopathology is thought to be mediated by serotype cross-reactive T cells 
dominating the immune response during acute secondary DENV infections, 
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instead of serotype-specific T cells. It has been proposed that the skewed T cell 
responses to DENV epitopes after secondary DENV infection could be explained 
by the individual‟s infection history and DENV-specific memory T cell original 
antigenic sin (Mongkolsapaya et al., 2003).  
 
Most of the peptides that we used (14/19) contain regions of the NS3 protein 
that have been characterized as DENV-specific T cell epitopes (Table 4.3) in 
previous studies (Simmons et al., 2005; Appanna et al., 2007). However, some 
peptide sequences seem to be new T cell epitopes not reported earlier to our 
knowledge (Simmons et al., 2005; Appanna et al., 2007). These putative novel T 
cell peptide epitopes cluster within positions 514-535 and 1913-1940. Some 
previously described epitopes are found in regions flanking positions 514-535 but 
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Table 4.3. Sequences of NS3 peptides assayed by IFN-γ ELISPOT in this study 
that overlapped at least 2 amino acids with previously reported T cell DENV 
epitopes in humans.  
















 A*03/11 Appanna 
et al., 
2007 












CD4 HLA-DR15 Simmons 
et al., 
2005 










  Simmons 
et al., 
2005 
VPNYNLIIMDEAHFT275-289 MRLLSPVRVPNYNLI   Simmons 
et al., 
2005 
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CD8 B*35 Simmons 
et al., 
2005 









a numbering of amino acid positions based on sequence alignments of DENV2 
serotypes 
b underlined sequences correspond to sequences present in peptides used in 
previous studies; amino acids in boldface indicate variants in the sequence of 
peptides used in present study 
c,d T cell subset responding to peptide stimulation and HLA restriction are 
indicated if known 
 
 
4.2.3 Comparison of ELISPOT with direct ex vivo- plating and restimulated cells  
We were interested to compare T cell response of PBMCs that were 
restimulated in vitro (by pre-incubation with peptides) before ELISPOT with that 
of cells plated directly ex vivo into ELISPOT plates. PBMCs from healthy dengue-
immune persons were cultured with individual peptides for 5 days at 105 cells in 
200μl/well RPMI 1640 (10%FCS; without IL-2) before ELISPOT. Some PBMCs 
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were cultured for 2 days with individual peptides then a portion was used in 
ELISPOT assay. The remaining cells were pooled according to individual 
peptides (used to stimulate them) that comprise the peptide pools as described in 
Materials and Methods. These were further kept in culture by incubating with the 
corresponding peptide pools and added with IL-2. After 9 days since the start of 
culture, ELISPOT assays were done with the individual peptides comprising the 
peptide pool.  
 
Some PBMC samples gave responses only after pre-incubation with 
individual peptides for 5 days, or were cultured, prior to ELISPOT (Figure 4.21). 
This broadened the extent of responses to all 19 peptides, whereas without pre-
incubation no response for some peptides was detected.  Samples that already 
responded even without pre-incubation gave stronger responses when pre-
incubated (Figure 4.21). The increase in the extent and magnitude of responses 
of pre-incubated PBMCs could be attributed to the expansion of DENV-specific T 
cells, which are present in frequencies that were below detection limit.   
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      A  
     B  
Figure 4.21. T cell responses to individual DENV2 NS3 consensus sequence peptides. T cell responses when PBMCs were directly used in 
ELISPOT assay without 5-day pre-incubation with peptides (A) increased in the breadth and magnitude when PBMCs were 
subjected to pre-ELISPOT in vivo sensitization with individual peptides. Peptides added to each well are indicated in red 
numbers and are the same for each donor. The controls are indicated by red boxes (left-positive control; middle-negative 
control; right-no cells added). 
   
   
   
   
   
   
   











         1            2            3            4            6            7            10          11          12          14          15           16 
 
 
        17         18           19          20          21          22           23 
138 | P a g e  
 
4.3  T cell line establishment 
 
Next, we established T cell clones by antigen restimulation ex vivo to be able 
to study T cell aspects that cannot be addressed in peripheral blood due to very 
low frequency of DENV-specific T cells. Expanded T cell clones could be used to 
study intracellular IFN-γ production by flow cytometric assay in response to 
antigen stimulation. They could also be expanded to sufficient numbers for T cell 
proliferation and T cell function (e.g. cytotoxic activity) assays. 
 
PBMCs from selected healthy dengue-immune individuals were used to set 
up a bulk culture of DENV-stimulated cells from which DENV-specific T cell lines 
were established. Cultures from Donor 76907, which gave responses to peptide 
pools spanning the highly conserved regions of the immunodominant NS3 
epitope of DENV2 majority consensus sequence (described for ELISPOT 
analysis) as determined by intracellular staining for IFN-γ and flow cytometry, 
were chosen for further culture. Diluted (50 cells/well) cells were cultured with 
peptide pool-pulsed γ-irradiated (2000 rad) autologous PBMC on culture days 12 
and 32, and were maintained until day 84. Half of the medium was replaced 
every time it turned yellow, maintaining the same final concentrations of peptide 
pools and IL-2 as described in Materials and Methods. All diluted cell culture 
wells exhibited evidence of cell expansion and survival on day 55. Selected wells 
were analyzed for intracellular IFN-γ and flow cytometry on days 55 and 57. 
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 Figure 4.22 shows the phenotypic analyses of cells by flow cytometry after 
intracellular staining for IFN-γ. 
 
The phenotypes of cells in selected diluted culture wells and their 
intracellular IFN-γ responses to restimulation with peptide pools at day 55 and 57 
are shown in Figures 4.23 and 4.24, respectively. Flow cytometry analysis was 
performed using the gating strategy described in Figure 4.19.  
 
On day 55, Live CD4+ and CD8+ lymphocytes were present in diluted 
culture, suggesting that the DENV peptides were recognized (Figure 4.23). Since 
the culture wells initially contained only approximately 50 cells/well on day 12, the 
cells present were CD4+ and CD8+ T cell clones that expanded from the diluted 
cells. Yet, there are also T cells present from the irradiated PBMCs. 
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Figure 4.22. Flow cytometry analyses for intracellular IFN-γ staining of stimulated 
and non-stimulated cultured PBMCs. Lymphocytes defined by FSC and 
SSC (A) were gated into IFN-γ+CD4+ (B) and IFN-γ+CD8+ (C) 
populations. Non-stimulated CD4+ (D) and CD8+ (E) cells do not produce 
IFN-γ.  At most 20 000 events were acquired. (continued on next page). 
  






























































      
 
Figure 4.22 (continued from previous page). Flow cytometry analyses for 
intracellular IFN-γ staining of stimulated and non-stimulated cultured 
PBMCs. Lymphocytes defined by FSC and SSC (A) were gated into IFN-
γ+CD4+ (B) and IFN-γ+CD8+ (C) populations. Non-stimulated CD4+ (D) 
and CD8+ (E) cells do not produce IFN-γ.  At most 20 000 events were 
acquired. Dot plots of stimulated and non-stimulated are different in terms 
of CD4 and CD8 staining because the figures shown were taken from the 




Whereas high frequencies of CD4+ lymphocyte clones were present in 
cultures with peptide pools 1-5, high frequencies of CD8+ lymphocytes were 
observed only in cultures with peptides 2, 3, and 4 (Figure 4.23). Very few CD8+ 
lymphocytes were present in cultures with peptide pool 5, while no more CD8+ 
cells were observed in cultures with peptide pool 1 (Figure 4.23). It seems that 
peptides in peptide pools 1-5 could efficiently maintain CD4+ lymphocyte clones 
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through cell growth promoting signals, while only the peptides in pools 2, 3, and 4 
could efficiently maintain CD8+ lymphocyte clones. 
 
Very low frequencies of IFN-γ-producing cells were observed among the 
clones (Figure 4.23). The clones may be DENV-specific lymphocytes that did not 
produce IFN-γ upon peptide stimulation but were maintained by the presence of 
the antigens through cell growth-promoting signals. 
 
On day 57, CD4+ lymphocytes were maintained in cultures re-stimulated with 
peptide pools 1-5, with few INF-γ+ CD4+ cells (Figure 4.24). Very low 
frequencies of IFN-γ-producing cells were observed among the clones. Very few 
CD8+ lymphocytes were observed in all diluted culture wells analyzed (data not 
shown). This indicates that the peptides that we used could maintain CD8+ 
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Figure 4.23. Phenotypes of the sub-cloned peptide pool-restimulated cultured 
cells analyzed at Day 55 by flow cytometry after intracellular IFN-γ staining. 
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With Peptide pool 3 









































































With Peptide pool 4 









































































Figure 4.23. Phenotypes of the sub-cloned peptide pool-restimulated cultured 
cells analyzed at Day 55 by flow cytometry after intracellular IFN-γ staining. 





145 | P a g e  
 
With Peptide pool 5 










































































Figure 4.23 (continued from preceding page). Phenotypes of the sub-cloned 
peptide pool-restimulated cultured cells analyzed at Day 55 by flow cytometry 
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With Peptide pool 1 








































































With Peptide pool 2 









































































Figure 4.24. Phenotypes of the sub-cloned peptide pool-restimulated cultured 
cells analyzed at Day 57 by flow cytometry after intracellular IFN-γ staining. 
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With Peptide pool 3 


















































































































































Figure 4.24 (continued from preceding page). Phenotypes of the sub-cloned 
peptide pool-restimulated cultured cells analyzed at Day 57 by flow 
cytometry after intracellular IFN-γ staining. CD4+ T cell clones are 
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With Peptide pool 5 









































































Figure 4.24 (continued from preceding page). Phenotypes of the diluted peptide 
pool-restimulated cultured cells analyzed at Day 57 by flow cytometry after 




The rest of the diluted culture wells that were not yet assayed were further 
cultured, as the surviving presumptive CD4+ clones might still expand to 
numbers sufficient for other assays. No indication of further cell expansion was 
observed. On day 84, all diluted cultures were analyzed.  
 
 No CD8+ clones were observed (data not shown). CD4+ lymphocyte clones 
were present in cultures re-stimulated with peptide pools 1-5, where IFN-γ+ 
CD4+ cells were observed (Figure 4.25). The frequencies of CD4+ lymphocytes 
at day 84 was lower compared with those on days 55 and 57. The clones did not 
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further expand, presumably due to lack of stimulation, as addition of peptide-
pulsed irradiated autologous PBMCs was done only until day 32. T cells become 
smaller and enter a resting stage between 10 and 14 days following the last 
stimulation with feeder cells (Current Protocols in Immunology, 2005). 
 
Whereas lymphocyte clones were maintained in culture after a particular 
period of time, the frequencies of IFN-γ+ lymphocytes were low. The cells could 
have stopped producing IFN-γ even after re-stimulation. The presumptive CD4+ 
clones could have lost their reactivity to the peptide antigens. Reactivity of T cell 
clones to antigens can be maintained by stimulating them with irradiated 
autologous PBMCs every 4 weeks (Current Protocols in Immunology, 2005). We 
did not have enough autologous PBMCs hence we were able to add peptide-
pulsed feeder cells only until day 32 of culture. The cells could have also stopped 
producing IFN-γ probably due to IL-10, a cytokine synthesis inhibitory factor that 
could have been produced by the lymphocytes in culture. The cell culture 
supernatants were collected and kept to measure IL-10. However, there was no 
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Figure 4.25. Phenotypes of the sub-cloned peptide pool-restimulated cultured 
cells analyzed at Day 84 by flow cytometry after intracellular IFN-γ staining. 
Presumptive CD4+ T cell clones are encircled. IFN-γ+ cells are boxed.  
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With Peptide pool 3 









































































With Peptide pool 4 









































































Figure 4.25 (continued from preceding page). Phenotypes of the diluted peptide 
pool-restimulated cultured cells analyzed at Day 84 by flow cytometry after 
intracellular IFN-γ staining. Presumptive CD4+ T cell clones are encircled. 






152 | P a g e  
 









































































Figure 4.25 (continued from preceding page). Phenotypes of the diluted peptide 
pool-restimulated cultured cells analyzed at Day 57 by flow cytometry after 
intracellular IFN-γ staining. Presumptive CD4+ T cell clones are encircled. 
IFN-γ+ cells are boxed. 
 
 
4.4 Flow cytometry analysis of intracellular IFN-γ T cell 
responses to DENV2 NS3 antigen peptides after ex vivo 
restimulation 
 
PBMCs from dengue-immune individuals were also tested for IFN-γ 
responses by intracellular cytokine staining after re-stimulation with peptide pools. 
In contrast to the attempt to establish T cell clones, these cultures were re-
stimulated with peptides in the absence of irradiated autologous PBMCs. PBMC 
(1X105) from different dengue-seropositive healthy individuals were cultured for 
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23 days with peptide pools.  PBMCs re-stimulated with peptide pools for 5 h were 
assayed for intracellular IFN-γ production by flow cytometry at days 7 and 23.  
 
Figure 4.26 summarizes how the different lymphocyte populations and the 
phenotypes of these cell populations were analyzed by flow cytometry. 
 
Only one (donor 16116) out of 3 PBMC donors gave detectable IFN-γ 
responses on day 7 (data not shown). The intracellular IFN-γ CD4+ and CD8+ T 
cell responses of PBMCs from Donor 16116 to peptide pools are shown in Figure 
4.27. 
 
Re-stimulation with the peptide pools induced detectable IFN-γ+ CD8+ T cells 
and CD4+ T cells (Figure 4.27). Peptide pool 5 induced the highest percentage of 
IFN-γ+ CD4+ T lymphocytes. Peptide pools 1 and 3 also produced IFN-γ 
responses in CD4+ t cells that are greater than that observed in the negative 
control. In CD8+ T cells, peptide pools 1, 2, and 5 induced IFN-γ+ cells, with 
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Figure 4.26. Gating strategy to define IFN-γ-producing CD3+CD4+ and 
CD3+CD8+ T lymphocytes. Lymphocytes defined by FSC and SSC (A), 
setting CD3+CD4+ (B) and CD3+CD8+ (C) gates on this population. Gates 
were set on these populations to define IFN-γ+CD3+CD4+ (D) and IFN-
γ+CD3+CD8+ (E) T lymphocytes. At most 20 000 events were acquired. 
 
















































































































































































































Figure 4.27. (Top) Representative flow cytometry analysis of intracellular IFN-γ T 
cell responses of peptide-stimulated PBMCs from Donor 16116. Gates 
define IFN-γ+ CD8+ T cells (A) and IFN-γ+ CD4+ T cells (B). (Bottom) 
Percentage of IFN-γ+ CD3+CD4+ and CD3+CD8+ T cells. 
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Cells from Donor 16116 were further cultured until day 23. In addition to 
intracellular IFN-γ staining and flow cytometry, the cultures were analyzed by 
IFN-γ T cell ELISPOT.  
 
Peptide pools 1 and 5 induced IFN-γ+ CD4+ T cells with percentages higher 
than that of the negative control. Peptide pool 2 induced the highest percentage 
































































































































Figure 4.28. Percentage of IFN-γ+ CD4+ and CD8+ T cells on cultured PBMCs at 
23 days culture days after re-stimulation with peptide pools. 
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Result of IFN-γ ELISPOT on cells from the same donor supported intracellular 
IFN-γ staining and flow cytometry data. Here, the individual peptides from 
peptide pool 2 (peptides 6, 7, 10, and 11), evoked T cell responses, with peptide 
6 eliciting the strongest responses (Figure 4.29). Peptide 6 (NS3 
MCHATFTMRLLSPVR (261-275)) contains amino acids that overlap with previously 
reported immunogenic human T cell determinants known to evoke responses 
from CD4+ T cell subsets (Simmons et al., 2005; Kurane et al., 1993; Okamoto et 
al., 1998). This peptide is found within the highly conserved (78%) NS3 amino 
acid stretch 200-324, where most antigenic peptides were identified by Simmons 
et al., (2005). This peptide could be further studied, as it might contain epitopes 
efficiently presented on common HLA types present in the Singaporean 
population and might be widely recognized by T cells.  Published epitopes which 
overlap with the sequence of peptide 6 are restricted by HLA-DPw2 (Kurane et 
al., 1993; Okamoto et al., 1998).  For a further characterization, HLA restriction 
for this peptide could be determined and responses to this epitope could be 
detected to determine if this is a dominant epitope.  
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Figure 4.29. IFN-γ T cell ELISPOT response of cultured PBMCs from Donor 
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Dengue virus infections cause significant morbidity and mortality in the 
tropics and subtropics globally. Gaps in the understanding of the pathogenesis of 
dengue disease exist, partly due to a lack of suitable experimental models, which 
impede the development of antiviral drugs and effective vaccines. The degree of 
immune responses correlates with severe dengue disease. NK cells, NKT cells, 
and T lymphocytes are important players in antiviral immune responses and may 
be critical eliminating DENV or may contribute to immunopathology.  
 
As part of the on-going prospective EDEN study, we analyzed NK cells, 
CD56-expressing T cells, and T lymphocytes longitudinally in fresh whole blood 
samples from dengue and febrile non-dengue patients from fever onset to 
convalescence. We also examined IFN-γ T cell ELISPOT responses in PBMCs 
from dengue patients and healthy dengue-immune individuals to peptides 
spanning the DENV2 NS3 antigen. Next, we established T cell clones by ex vivo 
antigen re-stimulation to study T cell aspects that cannot be addressed in 
peripheral blood due to very low frequency of DENV-specific T cells. Finally, we 
analyzed intracellular IFN-γ T cell responses to DENV2 NS3 antigen peptides 
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5.1 Phenotypic analyses of DENV-induced NK cells, CD56-
expressing T cells, and T lymphocytes 
 
5.1.1 Activation of NK cells, CD56-expressing T cells, and T lymphocytes 
 
Our results revealed higher levels of NK cell, CD56-expressing T cell, and 
T cell activation in dengue patients than in febrile non-dengue controls, indicating 
that the observed immune activation is DENV-specific. The roles of NK cells and 
CD56-expressing T cells after DENV infection are not well-established. Human 
anti-DENV T cell responses have not been comprehensively investigated and 
correlates of protective anti-DENV T cell immunity are not well-documented thus 
far. 
 
5.1.1.1 NK cells and CD56-expressing T cells 
 
NK and CD56-expressing T cell activation was indicated by their 
expression of CD69. CD69 is one of the earliest cell surface molecules 
expressed following activation on monocytes (De Maria et al., 1994), T 
lymphocytes (Testi et al., 1989), NK cells (Lanier et al., 1988), and all 
hematopoietically-derived leukocytes (Testi et al., 1994). CD69 acts as a 
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costimulatory molecule in cell proliferation, lymphokine secretion, and cytotoxicity 
in activated T cells (Borrego et al., 1999). Previous studies have demonstrated 
that expression of CD69 on in vitro activated PBMCs is associated with the ability 
to stimulate proliferative T cell responses (Maino et al., 1995; Prince and Lape-
Nixon, 1997). Decreased CD69 expression in NK cells has been associated with 
the severe symptoms of chronic fatigue syndrome (Mihaylova et al, 2007). As in 
T lymphocytes, CD69 may be essential also in NK cell function. CD69 is 
expressed by NK cells following stimulation by cytokines (IFN-α, IL-2, IL-12) and 
mitogens (e.g. PMA) (Borrego et al., 1999). The role of CD69 in NK cell cytolytic 
activity has been shown in mice (Karlhofer and Yokoyama, 1991) and human 
(Moretta et al., 1991). It has also been demonstrated that anti-CD69 mAbs 
triggered NK cell proliferation, CD25 and intracellular adhesion molecule-1 
(ICAM-1) expression, TNF-α production, and Ca2+ mobilization in preactivated 
NK cells, in addition to activating NK cytotoxicity (Borrego et al., 1999). 
 
Despite their low number after dengue infection, significantly higher 
frequencies of activated NK cells and CD56-expressing T cells during the acute 
and defervescent phases of infection in dengue patients compared to febrile non-
dengue controls suggest that these cells are among the immune cells that are 
efficiently activated by DENV infection. This also indicates that DENV infection 
more efficiently activates NK cells and CD56-expressing T cells than do other 
febrile, non-dengue diseases. That activated cell responses peaked at the onset 
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of fever (acute phase) and decreased within the next 3-4 weeks (convalescence) 
imply that the peak population comprised mostly effector cells. The levels of 
activated NK cells at convalescence can be taken as baseline levels for healty 
individuals. 
 
The innate arm of immunity, mainly NK cells, serves a critical function 
during early responses to infectious agents including viruses. They serve as 
sentinels of the immune system, act as primary responders, and alert the body to 
the presence of pathogens. The antiviral effector mechanisms of NK cells include 
IFN-γ production and direct lysis of virus-infected cells (Lodoen and Lanier, 2006) 
to stop the spread of the virus and jumpstart the adaptive immune response to 
successfully clear the pathogen. That viruses develop mechanisms to evade NK 
cells highlights the important role of NK cells in fighting viruses. These strategies,  
include viral expression of MHC class I homologs, viral protein modulation of 
MHC class I expression, inhibition of activating receptor function, production of 
cytokine-receptor antagonists or cytokine-binding proteins (Orange et al., 2002). 
 
CD56-expressing T cells comprise less than 5% of peripheral blood T 
lymphocytes and include CD56+ T cells and classical NKT cells (Kelly-Rogers et 
al., 2006). CD56-expressing T cells demonstrate dual innate and adaptive 
immune functions, having features of both NK cells and T cells. They have been 
164 | P a g e  
 
shown to kill tumor cells via MHC-unrestricted perforin/granzyme-mediated 
cytolysis without prior antigenic exposure (Ortaldo et al., 1991; Pittet et al., 2000). 
These cells also secrete IFN-γ, TNF-α, and IL-4 and display T cell-like cytotoxic 
activities restricted by MHC or CD1d and mediated by TCR (Ortaldo et al., 1991; 
Jin et al., 1998; Doherty et al., 1999; Ohkawa et al., 2001). 
 
NKT cells generally comprise only 0.5 to 1% of the peripheral blood 
mononuclear cells, but they compensate for their low numbers by producing 
more of IL-4 and IFN-γ than do CD4+ and CD8+ T lymphocytes (Ho, 2007). NKT 
cells are rapidly acting, releasing cytokines within 30 minutes of activation by lipid 
antigens. Activated NKT cells release a cascade of cytokines and chemokines, 
boost NK cell and T cell activity, support dendritic cell maturation, and promote 
polyclonal antibody production (Godfrey and Kronenberg, 2004; Galli et al., 2003; 
Gillesen et al., 2003; Nishimura et al., 2000; Carnaud et al.,1999; Tomura et al., 
1999). NKT cells are highly activated cells and differ from other immune cells by 
their continuous expression of CD69 in the absence of exogenous stimulation 
This could explain why at DK2 there is still CD69 expression, compared to 
CD56+CD3- cells. This is believed to result from the persistent stimulation by a 
self ligand, ensuring that NKT cells are always ready to respond (Godfrey and 
Kronenberg, 2004; Ho et al., 2004).  
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NKT cells have been shown in mouse studies to be protective against 
various infections, including viruses (Godfrey et al., 2000; Kronenberg and Gapin, 
2002). The role of NKT cells in human infections is not yet well understood. NKT 
cells with defective cytokine secretion have been linked to the inability to 
eliminate infectious agents and tumors in humans and mice (Brigl and Brenner, 
2004; Kronenberg, 2005). Several studies have observed depletion of 
Vα24/Vβ11 NKT cells in the peripheral blood of HIV-infected patients relative to 
healthy individuals (Fleuridor et al., 2003; Motsinger et al., 2002; Sandberg et al., 
2002; van der Vliet et al., 2002), and are probable targets of HIV (Fleuridor et al., 
2003). NKT cells quickly produce huge quantities of IFN-γ and IL-4 and may 
bridge innate and adaptive immunity.  
 
CD56-expressing “innate lymphocytes” that display innate and adaptive 
functional phenotypes could serve as the first line of defense against a broad 
spectrum of infectious agents including viruses and could potentially regulate 
adaptive immunity against these pathogens. Such roles in the body could be 
underscored by the phenotypic changes and quantitative and functional 
deficiencies of CD56-expressing T cells observed in hepatitis B (Barnaba et al., 
1994), hepatitis C (Deignan et al., 2002) and HIV (Tarazona et al., 2002) viral 
infections.   
 
So far, nothing is known about the role of CD56-expressing T cells in 
dengue infection. The early activation of CD56+CD3+ NK T cells in this study 
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indicates that it may be important in determining disease outcome. Since most of 
the patient samples we analyzed have mild dengue, the activation of NK cells 
and CD56-expressing T cells may signify good prognosis.  
 
The absolute count of activated cells may be more significant than %. In 
terms of absolute numbers, CD69+ NK cells did not differ between dengue and 
non-dengue patients. Interestingly, the absolute number of CD69+ CD56+CD3+ 
cells was significantly higher in dengue patients compared  to febrile non-dengue 
controls during defervescence. This suggests that activated CD56+CD3+ cells 
may be more important than NK cells in determining dengue disease outcome. 
 
 
5.1.1.2 T lymphocytes 
 
The current knowledge on human DENV-specific T cell responses derives 
from mouse studies, from in vitro re-stimulated patient cells, and from patient-
derived T cell lines. Activated effector cells are expected to associate with an 
acute viral infection like DENV infection. To assess the magnitude and kinetics of 
T cell responses, we analyzed the expression of CD38, an activation marker 
expressed by activated effector T cells but not by quiescent memory cells, in 
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dengue and febrile non-dengue patients. Investigating longitudinally the 
expression patterns of CD38 on CD3+ lymphocytes, we observed significantly 
higher percentages of activated CD45RA- (memory) CD3+CD4- (presumptive 
cytotoxic T cells), CD45RA+ (naïve/effector memory) CD3+CD4- (presumptive 
cytotoxic T cells), and CD45RA- (memory) helper T cells (CD3+CD4+) in dengue 
patients than in febrile non-dengue controls during the acute phase of infection. 
The frequencies of activated T cell subsets decreased between acute phase and 
convalescence.  
 
Our results imply that the activated T cell subsets are most likely DENV-
specific T cells that have been induced by DENV infection and contracted after 
viral clearance. We hypothesize that DENV infection elicits increased activation 
of innate immune responses observed in dengue patients during the acute phase 
of infection. Infected monocytes and DCs produce cytokines and migrate to 
lymph nodes to activate T cells. NK cells and CD56-expressing T cells are 
activated; activated NKT cells stimulate NK cells, DCs, APCs, B cells, and CTLs. 
Activated NK cells and NKT cells release cytokines, activating monocytes and 
DCs that migrate to secondary lymphoid organs to initiate T cell activation.  
Activated CD4+ T cells recognizing MHC class II-presented pathogen epitopes 
on DCs and macrophages secrete cytokines that activate B cells, elicit antibody 
production, determine antibody class switching, and activate cytotoxic T cells. 
Activated CD8+ T cells induce the death of virus-infected cells presenting MHC 
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class I-restricted virus epitopes via caspase-mediated apoptosis or through Fas-
mediated cell death, thus eradicating infected cells and resolving viremia. 
Activated CD8+ T cells also secrete the anti-viral and immunoregulatory cytokine, 
IFN-γ. Together, the activities of activated NK cells, CD56-expressing  T cells, 
and T lymphocytes result in DENV clearance. Activation of CD45RA- cells 
continues to defervescence, which might represent the new pool of memory cells. 
Upon viral clearance, T cell activation declines, the number of activated cells 
contract, and a subpopulation of antigen-specific cells differentiate into memory 
cells.  
 
We also did not observe significant difference in the percentages of 
activated cells between dengue patients with primary and secondary infection. 
This implies that DENV infection can stimulate naïve effector cells as efficiently 
as memory cells. This further suggests that severe disease can develop in 
primary or secondary infection, depending on whether immune activation is 
protective or contributes to pathology.  
 
 We did not analyze normal control subjects, However, the levels of 
activated cells during convalescence can be considered as baseline levels for 
healthy individuals. 
 
169 | P a g e  
 
5.1.2 Dengue-induced changes in T cell subpopulation phenotypes and in T cell 
differentiation stage 
 
Upon viral clearance, T cell activation decreases, the number of activated 
cells contract, and a subset of antigen-specific cells differentiate into memory T 
cells. Memory T cells persist long after the resolution of infection and quickly 
expand to large numbers of effector cells upon re-exposure to the related antigen.  
 
Monitoring immune responses during DENV infection entails knowing the 
function, distribution, and lineage relationships of T cell subpopulations. To 
address dengue-induced changes in T cell subpopulation phenotypes and in their 
stage of differentiation (naïve, effector), the expression of CCR7 and CD127, 
which define distinct phenotypes of effector and memory cells, were analyzed in 
PBMCs of dengue and febrile non-dengue patients.  
           
         The use of anti-CD 127 (IL-7 receptor alpha) antibodies can distinguish 
effector from memory cells. In the absence of antigen, naïve and memory cells 
need to survive and proliferate (Radziewicz et al., 2007). This process called 
“homeostatic proliferation” requires cytokines such as IL-7 and CD127 signaling 
(Fry and Mackall, 2005). Antigen-exposed naïve cells downregulate CD127 
expression (effector phenotype). Memory cells re-express CD127 for 
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maintenance upon antigen clearance. However, some memory CD8+ T cells 
express low CD127 levels in latent/chronic viral infections. Hence, these low 
CD127-expressing cells may not be true memory cells but may be effector cells 
among memory cells instead (Radziewicz et al., 2007). The most accurate way to 
distinguish effector from memory T cells may be to assess immediate cytotoxic 
activity (Wolint et al., 2004). CCR7 is a chemokine receptor that is required for 
homing of T cells to lymphoid tissue like lymph nodes and spleen. Cells that 
circulate between periphery and lymphoid structures will thus express CCR7, 
whereas CCR7-negative cells may remain in inflammatory tissue (Bromley et al., 
2005). 
 
The significantly lower percentage of CCR7+CD127+ (central memory) 
CD8+ CD3+ (cytotoxic) T cells in dengue patients than in febrile non-dengue 
controls during the acute phase of infection could be due to the recruitment of 
large numbers of these T cells for the anti-dengue response that changed into 
the effector memory phenotype. The significant increase in the percentage of 
these cells only in dengue patients could mean that as viremia is resolved at 
defervescence, a proportion of cells expressing the central memory phenotype 
were newly formed and re-appeared in circulating blood.  
The significantly higher percentage of CCR7-CD127- (effector memory) 
CD8- CD3+ (presumptive T helper) cells in dengue patients than in the controls 
during the acute phase could be due to DENV-induced differentiation of memory 
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cells into effector cells. There was no significant difference in the percentages of 
the above T cell subsets between dengue patients with primary or secondary 
infection. In primary infection, the CCR7-CD127- phenotype may thus represent 
newly activated DENV-specific cells or effector memory cells of non-DENV 
specificity. After viral clearance, effectors cells contracted and a small subset 
differentiated into memory cells, the decreased percentage at convalescence. 
 
We could not specifically determine/demonstrate T cell differentiation 
(effector to memory transition) from our analysis/results. Although distinct 
phenotypes of effector and memory T cells based on CCR7 and CD127 
expression can be recognized, the transition from effector to memory cell 
phenotype may not happen simultaneously for the two markers. After the effector 
response peak at the acute phase of infection, effector to memory phenotype 
transition may occur progressively, going through a number of phenotypic 
changes over several weeks. Analyzing the expression patterns of a number of 
markers on T cells, Miller et al. (2008) observed that changes in the expression 
patterns of these markers occurred gradually, implying that T cell differentiation is 
not a series of distinct phenotypic phases, rather a continuous process (Miller et 
al., 2008).       
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5.1.3  Concluding remarks and outlook 
  
Our results show that there is significantly higher immune activation in 
dengue patients than in febrile non-dengue patients, indicating that this immune 
activation is DENV-specific. The expression of the activation marker CD69 in NK 
cells and NKT/CD56 expressing T cells paralleled the expression of the 
activation marker CD38 in T cells. It will be interesting to determine how the 
observed DENV-specific activation relates to other aspects of the immune 
response, such as B cell activation and neutralizing antibody titers in the same 
subjects. These projects are ongoing. 
 
Higher frequencies of cells expressing activation markers in dengue 
patients than in non-dengue controls suggest that analysis of immune activation 
could be used to visualize immune responses without prior knowledge of 
antigenic specificity.  Nonantigen-specific evaluation of these responses could be 
further validated by analyzing the expression of activation markers 
simultaneously with proliferation markers (e.g. Ki-67), markers of effector function 
(e.g granzyme, perforin), and migration markers (e.g. CCR5).  
 
To fully elucidate the roles of DENV-induced cells in protective or 
pathologic immunity, DENV-specific effector cells need to be identified and 
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isolated by DENV peptide-loaded MHC tetramers for T cells and α-GalCer-
loaded CD1d tetramers for NKT cells and perform functional assays in addition to 
phenotypic assays. For NK cells, percent lysis of DENV-infected target cells 
could be detected. The correlation of cell surface phenotypes of the DENV-
specific T cell subsets with their functional characteristics is important in 
understanding how they contribute to dengue protective or pathologic immunity.  
 
Showing direct relationship between quantitative and qualitative measures 
of antigen-specific T lymphocyte functions and the protective role of these cells in 
human viral infections remains a challenge. However, T cell functional studies 
have identified functional correlates of T cell protective immunity. T cell 
polyfunctionality has been demonstrated to contribute to protective immunity. 
HIV-specific CD8+ lymphocytes in HIV+ long-term non-progressors (LTNPs) 
were observed to have a diverse functional profile such as secretion of IFN-γ, 
TNF-α, IL-2, and MIP-1β and expression of the degranulation marker CD107a 
(Betts et al., 2006). High frequency of antigen-specific T cells have been 
observed in HIV+ patients with progressive disease, but the number of antigen-
specific cells secreting IFN-γ, TNF-α, CCL4, and CCL5 decreased (Kostense et 
al., 2001; Scott-Algara et al., 2005) indicating that high numbers of  antigen-
specific T cells alone may not be protective.  Broad functional responses of 
antigen-specific T cells may indicate efficient control of viral replication.   
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Cell surface phenotype and functional analyses should also be correlated 
with clinical information on disease severity. Our analyses included only one 
severe dengue case, hence we could not correlate our results with disease 
severity. A number of dengue patients with severe disease are needed for further 
analysis.  
 
Our results should stimulate further studies designed to figure out the 
critical components of DENV-specific protective immunity and to look for 
prognostic markers. High immune activation, combined with nonantigen-specific 
methods of assessing immune responses, and correlation with clinical disease 
severity data may be used as indicators of disease progression. Functional 
signatures of immune responses could be used to monitor disease in the clinical 
setting to predict disease outcome. Clinical correlates of T cell activation and 
effector functions with protection could also direct the design of vaccines to 
shape T cell responses and guide vaccine clinical trials. 
 
It is recommended that analysis of blood samples from healthy controls 
should be done in order to properly analyze the results obtained for dengue-
infected patients.  
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5.2  DENV-specific T cell responses to DENV-2 2 NS3 peptides 
 
The breadth and magnitude of T cell responses of dengue patients and 
dengue-immune individuals to DENV-2 NS3 peptides were analyzed by IFN-γ 
ELISPOT assays. A number of patient PBMCs responded to at least one of the 
19 overlapping peptides derived from the DENV-2 NS3 majority consensus 
sequence. DENV NS3 protein is the most predominantly recognized T cell target 
and contains the highest number of antigenic peptides.   
 
Cells from defervescent and convalescent patients and from one dengue-
seropositive healthy individual recognized a few peptides. This could be 
attributed to the established T cell repertoire which was specific to the peptides 
tested. Cells taken from dengue-immune healthy individuals or convalescent 
patients that did not recognize any of the peptides, responded to a few peptides, 
and/or gave weak responses may have T cell repertoires that are not very 
specific for the peptides we used, and that these peptides were not sufficiently 
immunogenic to cells from these donors. 
 
Mongkolsapaya et al. (2003) observed good ELISPOT responses to 
unrelated DENV peptides in PBMCs collected after defervescence (2-week and 
2-month follow ups) but low or absent responses in samples collected during 
acute hospitalization phase. Zivna et al. (2002) and Simmons et al. (2005) 
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observed strongest T cell responses from samples taken from patients after 
hospital discharge. Simmons et al. (2005) hypothesized that, antigens, maybe as 
immune complexes, could persist even after viremia had been resolved. When 
analyzing T cell responses to hepatitis C virus infection, Lechner et al. (2000) 
showed that despite being relatively prevalent, highly activated antigen-specific 
CTLs exhibited a “stunned” phenotype that did not secrete IFN-γ during the acute 
phase of infection. The response (IFN-γ production) returns following decrease in 
viral load, and this response is more common in long-term HCV-seropositive 
individuals who had cleared the virus, though these individuals had lower 
frequencies of HCV-specific CTLs compared with those observed in individuals 
during and after resolution of acute HCV infection (Lechner et al., 2000). These 
observations may explain higher responses were evoked in PBMCs from a 
convalescent sample and in samples taken from healthy DENV-seropositive 
individuals, eventhough most individuals were dengue-immune (i.e. had memory 
T cells in the acute phase). Our result with the healthy DENV-seropositive 
individual giving a response shows that T cell responses can be studied on 
PBMCs from healthy dengue-immune individuals from whom enough blood can 
be collected. Studies that require more blood volume, such as studying functional 
T cell responses to a large number of peptide antigens spanning the entire DENV 
genome, or establishing T cell lines that requires several occasions of stimulation 
with autologous PBMCs are difficult to study in patients where limited volumes of 
blood can be drawn.  
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Whereas all PBMC samples used in the ELISPOT assay were collected 
from dengue-immune individuals and were expected to contain DENV-specific T 
cells that can potentially produce IFN-γ in the presence of DENV antigens, most 
of the samples responded to only one or a few peptides and/or responded with 
low SFU. A possible reason for the low response is that most of the peptides that 
we used were not strongly antigenic to DENV-specific T cells from this PBMC 
sample. That PBMCs from the same patient taken during defervescence 
(3643DK2) recognized only 2 peptides and convalescence (3643DK3) not 
responding to any peptide, could argue for the weak antigenicity of the peptides 
to this patient‟s T cells. Different factors such as T cell repertoire, affinity of 
peptide for MHC, dissociation rate of peptide from MHC groove, and peptide 
transport to endoplasmic reticulum can influence immunodominance of epitopes. 
An individual`s immune system can also determine immunodominance in terms 
of efficiency of antigen processing. It is also possible that the number of DENV-
specific T cells in the patient PBMCs was too low to be sufficiently detectable and 
give high numbers of SFU. 
 
 
General statements about the differences in responses between mild and 
severe dengue cases cannot be made in this study because we had PBMC 
sample from only one severe dengue patient who had no previous DENV 
infection. The association of T cell responses to DENV antigens and disease 
severity is important to addressing questions about dengue immunopathology. 
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Previous studies observed that the magnitude of DENV-specific T cell responses 
significantly correlated with disease severity. Severe dengue disease during 
secondary infection has been linked to a spectrum of T cell activation markers 
(Kurane et al., 1991b; Green et al., 1999a; Green et al., 1999b; Green et al., 
1999c; Gagnon et al., 2002), as well as relatively elevated percentages of 
activated cross-reactive T cells (Zivna et al., 2002; Mongkolsapaya et al., 2003). 
Investigating functional T cell responses to peptides spanning DENV antigens, 
Appanna et al. (2007) reported a sevenfold increase in T cell response to one 
NS3 peptide in adult DHF patients compared to DF patients, whereas Simmons 
et al. (2005) did not observe an apparent relationship between the extent and 
magnitude of T cell response of adult DF and DHF patients and clinical disease 
severity. Differences in viral factors and patient ethnic backgrounds and 
variations in HLA, as well as the use of some unrelated epitopes, could account 
for differences between results of different studies.   
 
Generally, the specificity of T cell responses was donor-dependent. The 
breadth and degree of responses did not differ between dengue patients with 
primary and secondary infection. Furthermore, we did not observe correlation 
between the breadth and magnitude of responses. Taken together, our 
observations reflect the range of factors that govern T cell responses and 
immunogenicity and immunodominance of antigens. 
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Most of the peptides in our study contain regions of DENV NS3 that have 
been previously shown as DENV-specific T cell epitopes. Some of the peptide 
sequences could be novel T cell epitopes as these sequences have not been 
previously reported to our knowledge.  
 
Pre-incubation with individual peptides for 5 days, or culturing PBMCs 
prior to ELISPOT broadened the extent and magnitude of responses to peptides 
This could be attributed to the expansion of DENV-specific T cells, which are 
present in low frequencies to be detectable.  Godard et al. (2004) reported that 
for detecting CMV-specific CD8+ T lymphocytes, a six-day in vitro sensitization 
step before ELISPOT assay was more sensitive than the method where PBMCs 
were used directly in the assay. This pre-ELISPOT stimulation involved the 
addition of IL-2 2 days after cell culture commenced.  
 
 
5.2.1 Concluding remarks and outlook 
 
 T cells may have a role in protective immunity or immunopathology. 
Functional characterization of DENV-specific T cells could reveal DENV-specific 
T cell responses that define clinical protective immunity or immunopathology and 
could be used in clinical practice. T cell functional assays such as ELISPOT have 
led to the identification of functional signatures of immune response that correlate 
to protection or pathology. Using ELISPOT assay, further analysis of severe and 
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mild dengue cases and more samples with primary or secondary infection is 
needed to identify reliable prognostic markers for dengue. This requires the 
development of optimized and standardized ELISPOT protocols. 
  
 
Interestingly, some T cell peptide epitopes have been associated with 
severe disease (Zivna et al., 2002; Mongkolsapaya et al., 2003). To aid the study 
of T cell responses to epitopes, a collection of well-characterized DENV T cell 
epitopes and their corresponding HLA restriction should be created.. This peptide 
library could facilitate studies on the protective or pathologic role of DENV-
specific T cells by studying the magnitude of responses to epitopes. Integrating T 
cell responses with clinical disease parameters and severity data will allow the 
identification of protective and/or pathologic epitopes and could help direct the 
rational design of vaccines against dengue.     
 
5.3  T cell line establishment  
 
We established T cell clones by antigen re-stimulation ex vivo to be able 
to study T cell aspects that cannot be addressed in peripheral blood due to very 
low frequency of DENV-specific T cells. PBMCs from selected healthy dengue-
immune individuals were used to set up a bulk culture of DENV-stimulated cells 
from which DENV-specific T cell lines were established.  
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Cultures from one donor which gave intracellular IFN-γ responses after initial re-
stimulation with peptide pools containing peptides that span the DENV-2 NS3 
protein (described for ELISPOT analysis), were diluted to approximately 50 
cells/well. These diluted cells cultured with peptide-pulsed γ-irradiated 
autologous PBMCs on days 12 and 32 were maintained until 84 days in culture.  
Analysis for intracellular IFN-γ and flow cytometry showed CD4+ and CD8+ 
lymphocyte clones that expanded and survived in most peptide pools after 55 
days in culture, with very few IFN-γ+ cells. At day 57, only CD4+ lymphocyte 
clones were observed, with very few IFN-γ+ cells. The rest of diluted culture wells 
that were not yet assayed were further cultured, anticipating the expansion of 
surviving CD4+ lymphocyte clones. After 84 days in culture, no indication of 
further cell expansion was observed, although cell survival was indicated by 
medium color change. CD4+ lymphocyte clones with IFN-γ+ cells were observed, 
although the frequencies of the clones were lower than those of lymphocyte 
clones on days 55 and 57. The low frequencies of IFN-γ+ lymphocytes suggest 
that these cells stopped producing IFN-γ even after restimulation, probably losing 
their reactivity to the peptide antigens. Loss of reactivity to antigens could result 
from a limited number of the addition of peptide-pulsed feeder cells or due to the 
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5.3.1 Concluding remarks and outlook 
 
T cell clones could be used to study T cell functions such as intracellular IFN-
γ production in response to antigen stimulation, which could be analyzed by flow 
cytometry. They could also be expanded to sufficient numbers for T cell 
proliferation and T cell function (e.g. cytotoxic activity) assays. They are 
important tools in studying the roles of T cells in immune responses. T cell clones 
are used to characterize T cell subpopulations based on distinct functional 
features. They may not be completely comparable to their normal parent T cells 
but they are nevertheless physiologically more significant than tumor cell-derived 
and immortalized cells (Current Protocols in Immunology, 2005). Normal, non-
transformed T cell clones are best propagated in long-term culture by re-
stimulating them with allogeneic feeder cells. Alternatively, EBV-B cells are used 
as APCs.  
 
Our T cell culture methodology succeeded in establishing CD4+ T cell clones. 
This protocol could be further improved and refined in order to make clones to 
expand to numbers sufficient for further assays and for expanding and 
maintaining CD8+ lymphocytes. As the role of T cells in protective immunity or 
immunopathology remains incompletely defined, functional characterization of 
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DENV-specific T cells using T cell clones could reveal DENV-specific T cell 
responses to identify reliable prognostic markers for dengue.  
 
 
5.4 Flow cytometry analysis of intracellular IFN-γ T cell 
responses to DENV-2 NS3 antigen peptides after ex vivo 
re-stimulation 
 
IFN-γ responses of cultured PBMCs (in the absence of irradiated autologous 
PBMCs and cultured for less prolonged times) from dengue-immune individuals 
were also tested by intracellular cytokine staining after re-stimulation with peptide 
pools. Only one out of 3 PBMC donors gave detectable IFN-γ responses of CD4+ 
and CD8+ T cells on day 7, with the highest responses CD4+ T cell responses to 
peptide pool 5 and CD8+ T cell responses to peptide pool 2. After 23 days in 
culture, peptide pools 1 and 5 induced IFN-γ+ CD4+ T cells with percentages 
higher than that of the negative control, while Peptide pool 2 induced the highest 
percentage of IFN-γ+ CD8+ T cells.  
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On day 23, additional analysis of cells from the same donor by IFN-γ T cell 
ELISPOT supported intracellular IFN-γ staining and flow cytometry data. The 
individual peptides from peptide pool 2 (peptides 6, 7, 10, and 11), evoked T cell 
responses, with peptide 6 eliciting the strongest responses. Peptide 6 (NS3 261-
MCHATFTMRLLSPVR-275) contains amino acids that overlap with previously 
reported immunogenic human T cell determinants known to evoke responses 
from CD4+ T cell subsets. This peptide is found within the highly conserved 
(78%) NS3 amino acid stretch 200-324, where most antigenic peptides were 
identified by Simmons et al., (2005).  
 
5.4.1 Concluding remarks and outlook 
 
Peptide 6 could be further studied since it might contain epitopes efficiently 
presented on common HLA types present in the Singaporean population and 
might be widely recognized by T cells.  For a further characterization, HLA 
restriction for this peptide could be determined and responses to this epitope 
could be detected to determine if this is a dominant epitope. As some HLA alleles 
have been linked to susceptibility to DHF, identifying epitopes efficiently 
presented by such alleles could increase our understanding of the pathology of 
severe dengue disease. 
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